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1 SUMMARY 
 
1 SUMMARY 
 
Breast cancer is the most frequent malignant disease among women worldwide. 
The term “breast cancer” encompasses many forms, described by histology, 
differentiation grade and size of the tumor and biomarkers like hormone receptor and 
HER2 status. These breast cancer types differ in their clinical behavior and 
aggressiveness, and the assessment of the established biomarkers is sometimes 
insufficient to accurately predict relapse and survival of the individual patient. Therefore, 
the search for factors contributing to the development and progression of this disease is 
an important task.  
 
The malignancy and hence the prognosis of a tumor is significantly influenced by 
the division rate of the cells of which it is composed. Cell proliferation depends on the 
frequency of passage through the cell cycle, which is tightly regulated by complexes of 
cyclins with cyclin-dependent kinases and their inhibitors. Changes in the expression 
and interplay of cell cycle regulators are considered to be associated with the formation 
and progression of cancer. Besides steroid hormones like estrogen, recent data suggest 
that melatonin may also strongly affect cell cycle regulators thereby altering growth and 
survival of breast cancer cells. So does melatonin suppress the proliferation of breast 
cancer cells via its binding to the G-protein coupled melatonin receptor, MT1, which is 
followed by downregulation of estrogen-induced cyclin D1, a protein required for the 
cell’s transition from G1- to S- phase of the cell cycle. Additionally, other factors like 
nestin, a marker for neuronal stem cells, may also influence the progression of breast 
cancer, particularly as in breast tumors, upregulation of nestin expression is found in 
newly formed blood vessels.  
The focus of this thesis was to examine cell cycle regulators, MT1 and nestin with 
respect to their role as novel biomarkers in the prognosis of relapse and death of breast 
cancer patients. Another aim was to analyze the expression of melatonin metabolizing 
enzymes in breast tissue in order to identify patients likely to benefit from the 
antiestrogenic and antiproliferative properties of melatonin. 
 
The expression of cyclin A, D1 and E, the cyclin-CDK-activating phosphatase 
CDC25A, the cell cycle inhibitor retinoblastoma protein and the CDK-inhibitors p16INK4a, 
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p21waf1/cip1 and p27kip1 was immunohistochemically examined in malignant (Ca) and their 
adjacent non malignant (NCa) tissue specimens from 69 breast cancer patients. 
Immunohistochemical staining was regarded positive for CDC25A in 36, for cyclin A in 
20, for cyclin D1 in 40, for cyclin E in 12, for p16INK4a in 16, for p21waf1/cip1 in 25, for 
p27kip1 in 23 and for retinoblastoma protein in 30 of 69 Ca specimens. In NCa, only 
CDC25A, retinoblastoma protein and p27kip1 were regarded to be positive in 41, 21 and 
16 of 69 specimens. The expression of cell cycle regulators in Ca or NCa specimens 
was not related to the time from primary diagnosis to relapse or cancer-associated 
death. However, expression of CDC25A, cyclin A, cyclin E, p16INK4a and p27kip1 in Ca 
was associated with a shorter overall survival of patients at high risk of relapse than 
those being at low or intermediate risk.  
Breast cancer and adjacent non-malignant tissue specimens from 42 patients were 
also assessed for MT1 and nestin by double immunofluorescence staining with 
antibodies against MT1 and nestin. MT1 was detected in luminal and myoepithelial cells 
of milk ducts in 40 NCa and in tumor cells in 39 Ca specimens. Coexpression of MT1 
and nestin was found in myoepithelial cells in 38 NCa and 18 Ca specimens with intact 
milk ducts. In 22 Ca sections, MT1-nestin coexpression was found in tumor cells 
infiltrating the stroma and in vascular-like structures. Quantitative analysis of 16 
selected paired NCa and Ca samples revealed that the percentage of MT1-expressing 
cells was higher in 8, and lower in 6 invasive Ca as compared to adjacent NCa sections. 
MT1-nestin coexpressing cells in more than 10% of tumor cells was found in Ca 
specimens from patients being in an advanced tumor stage (TII/III) and at a higher risk 
of relapse.  
Immunohistochemical examination of a possible relation between MT1 and cyclin 
D1 was done in Ca specimens from 33 breast cancer patients, showing staining for MT1 
in 31 and cyclin D1 in 27 specimens. Cyclin D1 correlated positively with estrogen 
receptor expression, whereas no such correlation was found between MT1 expression 
levels and estrogen receptor status.  
Analysis of the mRNA expression of the melatonin-metabolizing enzymes CYP1A1, 
CYP1A2, SULT1A1 and SULT1A3 in malignant and non-malignant breast tissue 
specimens from 10 patients by quantitative real-time reverse transcription PCR showed 
that CYP1A1 was expressed only in 3 Ca and 1 NCa, while CYP1A2 mRNA was below 
the detection limit in all patients. SULT1A1 mRNA was observed only in 2 Ca and 1 
NCa specimens from 3 patients, while high SULT1A3 levels were found in all Ca and 
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NCa samples. Therefore, biotransformation of melatonin to 6-hydroxymelatonin sulfate 
is not a major pathway in breast cancer. 
In summary, cell cycle regulators, MT1 and nestin might have the potential for 
further refining the assessment of risk of relapse in breast cancer patients.  
Moreover, these results indicate that malignant and non-malignant breast tissue differ in 
their expression of cell cycle regulators, nestin and MT1. The low expression levels of 
melatonin metabolizing enzymes and high MT1 expression levels in breast cancer 
tissue strongly argue for a major role of melatonin in the progression of breast cancer. 
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Das Mammakarzinom ist die häufigste Krebsart der Frau weltweit und ist ein 
Überbegriff für maligne Tumore des Brustdrüsenepithels, die sich makroskopisch, 
mikroskopisch und molekulargenetisch unterscheiden. Diese Klassifizierung ist von 
großer Bedeutung da die einzelnen Tumore in ihrer Aggressivität und im Ansprechen 
auf eine bestimmte Therapie voneinander abweichen. Dennoch reichen die zurzeit 
etablierten Marker, wie z.B. Östrogenrezeptorstatus oder Tumorhistologie, nicht für die 
exakte Unterscheidung der zahlreichen Subtypen aus, da der Krankheitsverlauf des 
Patienten im konkreten Einzelfall anders als erwartet verläuft. Daher ist die Suche nach 
weiteren Faktoren, die zum Entstehen und Fortschreiten dieser Erkrankung beitragen 
und damit eine exaktere Vorhersage von Rezidiven, der Überlebenswahrscheinlichkeit 
sowie Ansprechen auf die Therapie ermöglichen, ein wichtiges Forschungsziel. 
Die Aggressivität und Prognose eines Tumors hängt entscheidend von der 
Teilungsrate seiner Zellen ab. DNA-Verdoppelung und Zellteilung werden im Zellzyklus 
von Komplexen von Cyclinen mit Cyclin-abhängigen Kinasen gesteuert, die durch die 
Phosphatase CDC25A aktiviert oder durch CDK-Inhibitoren, wie p16INK4a, p21waf1/cip1 
oder p27kip1, gehemmt werden. Die Cycline D und E sind für die fortschreitende 
Phosphorylierung und damit Inaktivierung des Retinoblastoma Proteins verantwortlich, 
was zur Freisetzung von E2F Transkriptionsfaktoren und damit zum Eintritt der Zelle in 
die S-Phase führt. Eine Veränderung der Expression oder Aktivität dieser 
Zellzyklusregulatoren ist daher mit der Entstehung und dem Wachstum von Tumoren 
assoziiert. Neue Studien zeigten, dass das Neurohormon Melatonin die östrogen-
induzierte Expression von Cyclin D1 und somit die Proliferation von Brustkrebszellen 
hemmt. Entscheidend für die wachstumshemmende Wirkung von Melatonin in 
Brustkrebszellen ist dabei die Expression des G-Protein gekoppelten 
Melatoninrezeptors MT1. Ein Protein, das vor allem in Tumorzellen und 
Gefäßneubildungen in hochaggressiven, schnell wachsenden Brusttumoren exprimiert 
ist, ist das Intermediärfilamentprotein Nestin. Nestin wurde ursprünglich in neuronalen 
Stammzellen identifiziert, in welchen die Aktivierung von MT1 zu erhöhter Proliferation 
und einer Hemmung der Apoptose führte. 
Das Ziel dieser Arbeit war die Untersuchung von Zellzyklusregulatoren, MT1 und 
Nestin und ihrer Rolle in der Pathogenese von Brustkrebs und als mögliche neue 
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Biomarker in der Vorhersage von Rezidiven und der damit verbundenen 
Überlebenswahrscheinlichkeit. Im Hinblick auf einen möglichen adjuvanten Einsatz von 
Melatonin als Substanz mit antiöstrogener und wachstumshemmender Wirkung in der 
Brustkrebstherapie war die Untersuchung von melatonin-metabolisierenden Enzymen 
im Brustkrebsgewebe ein weiteres wichtiges Ziel dieser Arbeit.  
Der erste Schritt dieser Arbeit umfasste die immunhistochemische Analyse der 
Expression von Cyclin A, D1 und E, CDC25A, p16INK4a, p21waf1/cip1, p27kip1 und 
Retinoblastoma Protein in malignem (Ca) und angrenzendem nicht-malignen (NCa) 
Gewebe von 69 Brustkrebspatienten mit hohem, mittlerem oder niedrigem Risiko ein 
Rezidiv zu entwickeln. Von 69 Ca Schnitten wurden 36 als positiv für CDC25A, 20 für 
Cyclin A, 40 für Cyclin D1, 12 für Cyclin E, 16 für p16INK4a, 25 für p21waf1/cip1, 23 für 
p27kip1 und 30 für das Retinoblastoma Protein befunden. Im angrenzenden NCa waren 
hingegen nur 41 Proben für CDC25A, 21 für p27kip1 und 16 für das Retinoblastoma 
Protein immunhistochemisch positiv, während keine Färbung für alle anderen 
Zellzyklusregulatoren gefunden wurde. Die immunreaktiven Scores der 
Zellzyklusregulatoren in Ca und NCa Schnitten waren nicht mit einem früheren Rezidiv 
oder Tod assoziiert. Allerdings zeigten Patienten mit positiver Färbung von CDC25A, 
Cyclin A, Cyclin E, p16INK4a und p27kip1 aus der Hochrisikogruppe ein kürzeres 
Gesamtüberleben als Patienten mit geringem bis mittlerem Rezidivrisiko.  
Ein weiteres Ziel dieser Arbeit war die Untersuchung von Ca und angrenzenden 
NCa Gewebsproben von 42 Brustkrebspatienten auf eine mögliche Koexpression von 
MT1 und Nestin mittels Doppelimmunfluoreszenzfärbung. Eine 
Immunfluoreszenzfärbung von MT1 in luminalen und myoepithelialen Zellen der 
Milchgänge war in 40 NCa und in Tumorzellen in 39 Ca Proben zu beobachten. 38 NCa 
und 18 Ca Schnitte zeigten eine Koexpression von MT1 und Nestin in den 
myoepithelialen Zellen intakter Milchgänge. Eine Koexpression von MT1 und Nestin 
wurde weiters in infiltrierenden Tumorzellen und kleinen Blutgefäßen in 22 Ca 
Gewebsproben beobachtet. Die quantitative Analyse von MT1-exprimierenden Zellen in 
ausgewählten Ca und dazugehörigen NCa Schnitten von 16 Patienten mittels der 
Bildanalysesoftware TissueQuest® zeigte, dass die Anzahl an MT1-positiven Zellen in 8 
Ca höher und in 6 Ca niedriger als im angrenzenden NCa ist. Ein besonders wichtiger 
Befund dieser Studie war, dass die Anzahl an Tumorzellen (> 10%) mit MT1-Nestin-
Koexpression im Stroma mit einem höheren Tumorstadium (TII/III) und einem höheren 
Rezidivrisiko assoziiert ist. 
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Eine mögliche Korrelation von MT1 mit Cyclin D1 im Brustkrebsgewebe wurde 
mittels immunhistochemischer Färbung von 33 Ca analysiert, und zeigte eine 
Immunfärbung von MT1 in 31 und von Cyclin D1 in 27 Brustkrebsschnitten. Eine 
Färbung beider Proteine, MT1 und Cyclin D1, wurde in 25 Ca Proben nachgewiesen, 
jedoch korrelierte der immunreaktive Score von MT1 nicht mit jenem von Cyclin D1. 
Die Expression der Melatonin-metabolisierenden Enzyme Cytochrom P450 (CYP) 
1A1, 1A2 und der Sulfotransferasen SULT1A1 und SULT1A3 in Ca und NCa von 10 
Brustkrebspatienten wurde mittels quantitativer Real-Time Reverse-Transkriptions-
Polymerasekettenreaktion untersucht. CYP1A1-mRNA war nur in 3 Ca und einem NCa 
exprimiert, während CYP1A2-mRNA in keiner Gewebsprobe enthalten war. SULT1A1-
mRNA wurde in 2 Ca und einer NCa Probe gefunden, die jedoch nicht mit den 
Patienten mit CYP1A1 Expression ident waren. Hingegen zeigten alle Ca und NCa eine 
Expression von SULT1A3-mRNA. Da die Hydroxylierung von Melatonin durch CYP die 
Voraussetzung für die nachfolgende Sulfatierung durch SULT ist, erlauben diese 
Ergebnisse die Schlussfolgerung, dass im Brustgewebe keine nennenswerte 
Metabolisierung und damit Inaktivierung von Melatonin zu 6-Hydroxymelatoninsulfat 
stattfindet.  
Zusammenfassend gibt die Bestimmung von Zellzyklusregulatoren, MT1 und Nestin in 
Brustkrebsgewebe wichtige Zusatzinformationen über das individuelle Risiko eines 
Brustkrebspatienten hinsichtlich Metastasierung und der damit verbundenen kürzeren 
Überlebenszeit. Darüber hinaus zeigen die Ergebnisse dieser Arbeit, dass sich 
malignes und nicht-malignes Brustgewebe in der Expression von Zellzyklusregulatoren, 
MT1 und Nestin unterscheiden. Die geringe Expression von Melatonin-
metabolisierenden Enzymen bei gleichzeitig hoher MT1-Expression im 
Brustkrebsgewebe deuten auf eine bedeutende Rolle von Melatonin in der 
Pathogenese von Brustkrebs. 
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3.1 Breast Cancer 
 
3.1.1 Anatomy and Histology of the Female Breast 
 
A. Anatomy 
The female breast is made up of a branching duct system, leading from the nipple 
to the milk glands. Up to twenty glandular units, termed breast lobes, are arranged in 
a radial pattern around the nipple (mammary papilla), and are surrounded by a 
dense, collagenous connective tissue. Lactiferous ducts connect each lobe with the 
mammary papilla, where they exit the breast via a secretory pore.  
Each lobe is composed of several smaller lobules, which are separated from 
each other by a loose, fibrous fatty connective tissue. The lobules consist of about 
twenty small glandular structures (acini) which drain through the terminal duct. The 
entity of acini and terminal duct is called the “terminal duct-lobular unit” (TDLU). 
During pregnancy, the alveolar ductules of the TDLU differentiate into the milk-
producing acini (Figure 1) (Junqueira et al 1996).  
 
 
Figure 1. Anatomy of the Female Breast. Branching system of ducts leading down from the nipple 
to the terminal duct lobular units (TDLU), which is composed of small milk glands. (Junqueira et al 
1996) 
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B. Histology 
The mammary gland is composed of glandular tissue and its surrounding 
connective tissue.  
In the glandular tissue, the ducts are made up of a single layer of epithelial cells 
lining the lumen (luminal cells), which is surrounded by a continuous layer of 
myoepithelial cells. The latter separates the luminal cells from the basement (basal) 
membrane and the stroma. By contrast, in the alveoli, some luminal epithelial cells 
are in direct contact with the basal membrane (Polyak and Hu 2005) (Figure 2). 
 
 
Figure 2. Sections from healthy human breast tissue, showing a terminal milk duct (TD), 
branching into several small, milk-producing, alveolar ductules (AD) (left, 25x magnification). 
The right picture shows the alveolar ductules at higher (250x) magnification. Both, terminal duct 
and alveolar ductuli are composed of an inner layer of secretory luminal cells (L) and an outer 
layer of myoepithelial cells (M) which adjoins to the basement membrane (BM). The basement 
membrane separates the ducts and ductules from the surrounding fatty fibrous connective 
tissue. Blue hematoxylin-staining denotes the cell nuclei, while the cytoplasm is stained red by 
eosin. (Moinfar 2007) 
 
 
The connective tissue, which surrounds the glandular tissue, is composed of 
blood and lymphatic vessels, nerves, adipose and fibrous tissue, and therefore 
multiple cell types, such as endothelial cells, smooth muscle cells, fibroblasts, blood 
cells, nerve cells and adipocytes are found in the breast stroma (Guinebretiere et al. 
2005). 
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3.1.2 Breast Cancer and its Histological Forms  
 
Breast cancer is the most common form of cancer among women, and makes up 
one third of all new cancer cases in Europe (reviewed by Karim-Kos et al 2008). 
Although the mortality rates have declined in the past two decades due to earlier 
detection and better treatment options, the morbidity is still increasing (Hilakivi-Clarke 
et al. 2004).  
 
The most common malignancies of the breast are adenocarcinomas arising from 
the epithelium of either the lobules or ducts. This can be explained by the fact that 
the mammary luminal epithelium is hormone-responsive due to its expression of 
estrogen- and progesterone-receptors, and underlies continuous changes within 
each menstrual cycle (reviewed by Clarke 2003).  
 
Around 50% of all breast carcinomas are located in the upper outer quadrant of 
the breast (Lee 2005). 
 
Histologically, various steps can be identified during the formation and 
progression of breast carcinomas. The increased proliferation of luminal epithelial 
cells results in ductal hyperplasia, which is still a benign condition. The cells may 
then transform to premalignant atypical cells with nuclei of varying shape and size, 
giving rise to the formation of a non-invasive, in situ, carcinoma being still confined to 
the milk ducts and lobules (reviewed by Purcell and Norris 1998). When the cells 
break through the basement membrane and the primary tumor spreads into the 
surrounding stroma, the tumor has become an “invasive carcinoma”. Now, the tumor 
cells may also invade lymphatics and blood vessels, giving rise to metastases in 
locoregional lymph nodes, but also in distant organs (reviewed by Beckmann et al 
1997).  
 
Due to their cellular morphology and tumor growth pattern, many distinct 
histological forms of breast cancer exist. In the following, the histological features of 
all breast carcinomas relevant for this thesis will be described.  
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Non-invasive breast cancers 
 
A. Ductal carcinoma in Situ (DCIS) 
The intraductal carcinoma is found in around 15-30% of carcinomas, and is four 
times more common than the lobular carcinoma in situ. DCIS results from 
proliferation of epithelial cells of the TDLU. Due to its high proliferation, the tumor in 
the TDLU extends, so that the terminal ducts resemble large ducts (Figure 3). Five 
morphological types of DCIS can be distinguished: solid, comedo, cribriform, 
papillary and micropapillary DCIS. These morphologic types differ greatly in their risk 
to become invasive, with comedocarcinoma having the highest and pure cribriform or 
micropapillary carcinomas having the lowest risk (Tavassoli 1992). 
 
 
 
 
Figure 3. Sections from breast carcinomas which are still confined to the milk ducts, 
without breaking in the surrounding stroma (ductal carcinoma in situ, DCIS), 20x 
magnification. Hematoxylin-blue stained tumor cell nuclei fill the milk ducts in a solid 
(left) and a cribriform (right) pattern of DCIS. In the cribriform DCIS, the tumor cells 
form fenestrations (arrows). Cytoplasma is stained red with eosin.  
(Sun et al. 2009) 
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B. Lobular Carcinoma in Situ (LCIS) 
Like DCIS, non-invasive lobular carcinoma originates in the TDLU. LCIS does not 
form a palpable mass and is therefore only randomly detected in patients biopsied for 
other reasons. This in situ carcinoma is very often multifocal and simultaneously 
found in both breasts (bilateral). If LCIS is left untreated, about one third of the 
lesions will become invasive within twenty years. Microscopically, LCIS is 
characterized by small uniform cells with sparse cytoplasm that fill the TDLU. Very 
few mitoses are seen (Tavassoli 1992). 
 
 
 
Invasive breast cancers 
 
Invasive carcinomas may be classified according to the relationship of tumor 
mass to the amount of connective tissue. Accordingly, medullary carcinomas contain 
a high tumor proportion, and scirrhous carcinomas a high amount of connective 
tissue. The carcinoma simplex contains equal proportions of tumor and connective 
tissue. 
Carcinomas with characteristic histological features are called invasive 
carcinomas of special type, and examples are the lobular, medullary, mucoid, tubular 
and apocrine invasive carcinoma. In the case of no special histological features, the 
carcinoma is designated “carcinoma not otherwise specified”, NOS (Moinfar 2007).  
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C. Invasive Ductal Carcinoma, NOS  
About 80% of breast carcinomas are of the invasive ductal (id) NOS type. 
Histologically, the tumor cells are larger than normal epithelial cells, and cluster to 
tubules or sheets (Figure 4). Mitoses, necrosis and calcification are often observed 
(Tavassoli 1992). 
 
 
 
 
 
Figure 4. Section from an invasive breast carcinoma 
originating from the large milk ducts, 100x magnification. 
D denotes a milk duct which is filled with blue-stained 
tumor cells (at the top, left) or which still shows a non-
malignant appearance (center). The tumor cells (arrows) 
have spread beyond the basement membrane of the 
ducts into the surrounding stroma. V, blood vessel. Blue, 
hematoxylin-stained cell nuclei; red, eosin-stained 
cytoplasma and stroma. (Song et al. 2006). 
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D. Invasive Lobular Carcinoma 
Invasive lobular (il) carcinoma accounts for about 10% of all invasive breast 
carcinomas and is the second most common type of invasive carcinoma. Infiltrating 
lobular tumors are often impalpable. In up to one third of cases, concurrent invasive 
carcinoma in the other breast might be possible. Microscopically, invasive lobular 
carcinomas consist of small uniform tumor cells which infiltrate as individual rows 
(Indian file) or show a concentric arrangement (Figure 5) (Tavassoli 1992). 
 
 
 
 
Figure 5. Section from an invasive breast carcinoma 
originating in the lobules, 200x magnification. This 
invasive lobular carcinoma is characterized by nearly 
uniform small tumor cells infiltrating the stroma in single 
rows (“Indian files”). Cell nuclei are stained blue with 
hematoxylin. Cytoplasma and stromal components are 
stained red with eosin. (Franceschini et al. 2006). 
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E. Medullary Carcinoma 
Around 5-7 % of all breast carcinomas are medullary carcinomas. Histologically, 
medullary carcinomas are characterized by large solid tumor cell conglomerates 
which are infiltrated by inflammatory cells. The tumor cells lack defined cell borders 
(syncytial pattern), and show large nuclei of variable form and shape with 
pronounced nucleoli. Mitotic activity is high. Hardly any glandular or fatty tissue is 
found within the invasive tumor (Figure 6) (Wargotz and Silverberg 1988). 
 
 
 
 
Figure 6. Section from an invasive medullary breast 
carcinoma, 100x magnification. No milk ducts are seen 
any more. Large tumor cells of varying size and shape 
are spread throughout the stroma. The tumor cells have 
pronounced nucleoli. Mitoses are commonly observed. 
The stroma is infiltrated with small, more intensely 
stained, lymphoid cells (left part of the picture). The blue 
color indicates hematoxylin-staining of cell nuclei, 
whereas cytoplasma and stromal components are 
stained red with eosin. (Milde et al. 2006). 
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F. Mucinous (Colloid) Carcinoma 
This small subset of breast carcinomas (~ 3%) mainly occurs in elderly women of 
> 75 years of age. Carcinomas of the colloid type are gelatinous and soft in their 
consistency, and are characterized by tumor cell clusters and single tumor cells 
floating in pools of extracellular mucin (Figure 7) (Tavassoli 1992). 
 
 
 
 
 
Figure 7. Section from an invasive mucinous breast 
carcinoma, 100x magnification. No ductal structures 
are any longer recognizable. Clusters of tumor cells 
(arrows) are floating in pools of extracellular mucin 
(unstained). Blue, hematoxylin-stained tumor cell 
nuclei; red, eosin-stained stromal components. 
(Moinfar 2007) 
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G. Tubular Carcinoma 
Tubular carcinomas account for about 2% of all invasive breast cancers, and 
represent a very well differentiated form of ductal carcinoma. Although being often 
impalpable, these tumors can be usually well detected by mammography. The term 
“tubular” refers to the arrangement of cells into small glands and tubules of variable 
shapes, which are randomly distributed in a fibroblastic stroma. The often angulated 
tubules display open lumens and are lined by a single layer of normally appearing 
epithelial cells with rare mitotic activity (Figure 8) (Tavassoli 1992).  
 
 
 
 
Figure 8. Section from an invasive tubular breast 
carcinoma, 200x magnification. The glands are made up 
by a single layer of carcinoma cells; myoepithelial cells 
have disappeared. The glands infiltrate into the 
surrounding stroma. Blue, hematoxylin-stained cell 
nuclei; red, eosin-stained stroma. (Esposito et al. 2007). 
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H. Apocrine Carcinoma 
Apocrine carcinoma is observed in about 0.5% of all breast carcinomas (Celis et 
al. 2006). This invasive carcinoma is composed of large cells with abundant 
eosinophilic granular cytoplasm surrounding large, hyperchromatic nuclei with 
pronounced nucleoli. Some carcinoma cells contain lipid droplets thereby simulating 
sebaceous cells (Figure 9) (Moinfar 2007).  
 
 
 
 
Figure 9. Sections from an invasive apocrine breast carcinoma. The left picture shows large 
heteromorphic tumor cells (arrows) invading the stroma, at 100x magnification. These cells 
are intensely stained with eosin, a red dye marking the alkaline components of cytoplasma. 
The tumor cell nuclei are only weakly stained with hematoxylin (blue). In the upper left part 
of the picture, the small dark-blue stained cells indicate an infiltration with inflammatory 
cells. The right picture shows a single tumor cell (TC) with abundant eosinophilic cytoplasm 
and three nuclei (arrows) of varying size and shape at 2500x magnification. Also, the 
nucleoli are visible. (Moinfar 2007) 
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3.2 Prognostic and Predictive Parameters in Breast Cancer 
 
According to the National Health Institute, a biomarker is “a characteristic that is 
objectively measured and evaluated as an indicator of normal biologic processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention” 
(Biomarkers Definitions Working Group 2001). Biomarkers are required for the 
diagnosis of breast cancer. By their assessment, breast cancer patients should be 
recognized as early as possible. Moreover, biomarkers should describe the clinical 
behavior of the tumor in order to identify patients at high risk of relapse and in order 
to select the optimal therapy. Biomarkers are therefore classified into “prognostic” 
and “predictive” factors [Oldenhuis et al 2008]. Prognostic parameters are 
determined in patients prior to chemotherapy and should give information on the 
patient’s particular course of disease, the risk of relapse and the probability of 
survival. By contrast, predictive factors should estimate whether a patient would 
benefit from a particular therapy or not [Oldenhuis et al 2008]. 
Below, biomarkers already established in routine are briefly described, followed 
by novel strategies. 
 
 
3.2.1 Prognostic and Predictive Markers in Breast Cancer Routine 
Diagnostics  
 
Traditional prognosticators include factors which describe characteristics of the 
tumor (histology, size, differentiation grade) and the patient (age, menopausal 
status), and molecular markers, like the receptors for estrogen and progesterone and 
the human epidermal growth factor receptor 2.  
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A. Histology 
The histological assessment of tumor specimens can contribute to predict the 
further course of disease, since the diverse histological breast cancer subtypes show 
a different clinical behavior. Patients with infiltrating ductal carcinomas of no special 
type have been shown to have the worst prognosis, followed by lobular and 
medullary carcinomas (Ellis et al. 1992). Pure mucinous carcinomas grow relatively 
slowly, so that 10 years after primary diagnosis, more than 90% of patients are still 
alive (Feiner and Moezzi 1999). Also, tubular carcinomas show a favorable prognosis 
(Ellis et al. 1992). Studies assessing the prognosis of patients suffering from apocrine 
carcinoma are contradictory (Celis et al. 2006). Apocrine carcinomas are often 
undifferentiated, high-grade tumors, a feature per se known to have a poor 
prognosis. However, the survival of patients with apocrine carcinoma does not seem 
to differ from other, non-apocrine, high grade breast carcinomas (Moinfar 2007).  
 
B. Grade 
The histological grade is an indicator for the degree of differentiation of a tumor. 
Well-differentiated, low-grade, tumors still resemble the tissue of origin while there is 
no such similarity observed for poorly differentiated, high-grade, tumors. There is a 
close relationship between the degree of differentiation and the aggressiveness of a 
neoplasm, with poorly differentiated tumors showing a higher proliferation rate and 
propensity for invasiveness than well differentiated ones. Therefore, the assessment 
of the tumor grade provides important prognostic information. Several grading 
systems are currently in use for breast cancer, of which the most common are the 
Scarff-Bloom-Richardson (SBR) system and the more modern Elston-Ellis 
modification of the SBR grading system (Nottingham grading system) (Bloom and 
Richardson 1957; Elston and Ellis 1991). They combine the extent of variation in size 
and shape of the tumor cells (nuclear pleomorphism), the presence of milk ducti 
(tubule formation) and the frequency of mitoses. The assessment of the tumor 
differentiation grade is shown in Table 1.  
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Features Criteria Score 
> 75 % 1 
10 – 75 % 2 Tubule formation 
< 10 % 3 
< 10 mitoses/10 HPF 1 
10 – 19 mitoses/10 HPF 2 Mitotic Count 
> 20 mitoses/10 HPF 3 
Small regular uniform cells 1 
Moderate nuclear size and variation 2 Nuclear Pleomorphism 
Marked nuclear variation 3 
 3 - 9 
Sum of Scores 
Grade Terminology 
3 – 5 G1 (”low grade”) Well differentiated 
6,7 G2 (“intermediate grade”) Moderately differentiated 
8,9 G3 (“high grade”) Poorly differentiated 
Table 1. Evaluation of the tumor differentiation grade according to Bloom and Richardson (Bloom 
and Richardson 1957). The breast cancer sections are viewed under a microscope at maximum 
magnification (HPF, high power field). For assessment of the grade, the following parameters are 
taken into consideration: the extent of glandular formation (tubule formation), the number of dividing 
cells (mitotic count) and size and shape of the tumor cell nuclei (nuclear polymorphism). To each of 
these parameters, a score from 1 to 3 is assigned and the scores are summarized to give the 
histological grade.  
 
C. Tumor Stage  
The cancer stage provides information on the extent of spread of the tumor and is 
regarded the most important predictor of survival (Marrazzoa et al. 2007). The most 
common staging system for breast cancer, used by the International Union against 
Cancer (UICC), the American Joint Committee on Cancer (AJCC) and the 
International Federation of Gynecology and Obstetrics (FIGO), is the TNM staging, 
which is an abbreviation for tumor, node and metastases. Tumor, T, refers to the 
size of the primary tumor and is given a number from 0 (< 2 cm) to 4 (> 5 cm). N 
represents the number and localization of regional lymph nodes with metastases and 
is ranked from 0 (no metastases in nodes) to 4 (Sobin and Wittekind 2002). 
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Remarkably, patients showing invasion of tumor cells into locoregional lymph nodes 
have a significantly poorer prognosis than those without nodal metastases 
(Fitzgibbons et al. 2000). Metastasis into distant organs is represented by the letter 
M, and is 0 if the tumor has not spread to distant organs or 1 if metastases are 
present (Sobin and Wittekind 2002). Additionally, very often, invasion into lymphatic 
(L) and blood vessels (V) is also evaluated and indicated (Sobin and Wittekind 2002).  
These factors (Tumor, Nodes, Metastases, Lymphatics and Venes) are then 
summarized to give the stage, which is expressed in Roman numerals. Stage I 
cancers are localized to one part of the body, while stage II and III cancers are locally 
advanced. Stage IV cancers have spread to other, more distant, organs.  
 
D. Estrogen and Progesterone Receptors (ER and PR) 
As estrogen and progesterone play an important role in breast physiology, they 
are also involved in its pathophysiology. Their effects are predominantly mediated via 
binding to their nuclear receptors ER and PR, which, upon activation, form dimers 
and function as transcription factors to regulate the expression of specific genes 
involved in cell proliferation (Figure 10). Remarkably, one ER target gene encodes 
for PR, and estrogen was shown to upregulate PR expression (Clarke 2004). The 
estrogen effects are mediated via two ER-subtypes, namely ER-α and ER-β, which 
are encoded by two different genes, giving rise to proteins which are very similar in 
their DNA binding domain but differ in about 42% in their ligand binding domain (Ruff 
et al. 2000). High levels of ER- β have been found in resting breast epithelium, while 
in proliferating breast tissue these levels are only low (Lofgren et al. 2006). Moreover, 
ER-β has been shown to counteract the proliferative effects of ER-α (Paruthiyil et al. 
2004). In analogy to ER, two subtypes of PR, PR-A and PR-B, encoded by a single 
gene, have been identified. It has been shown that PR-B activation results in 
enhanced cell proliferation which can be antagonized by PR-A (Conneely et al. 
2000).  
Selective estrogen receptor modulators (SERM) have a different affinity for ER-α 
and ER-β, and are effectively applied as adjuvant drugs in breast cancer 
chemotherapy. To predict the response to this endocrine treatment, the expression of 
both, ER and PR, is routinely determined by immunohistochemical (IHC) staining of 
breast cancer tissue sections in which the localization and distribution of ER and PR 
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is detected via binding of specific antibodies (Ravdin et al. 1992; Cui et al. 2005; 
Hayashi and Yamaguchi 2005). In addition to their role in prediction of therapy, the 
presence of hormonal receptors is also a favorable prognostic factor for overall 
survival. In this context, it has been shown that patients with ER-positive- but PR-
negative- tumors have a worse overall survival than those with carcinomas positive 
for both, ER and PR (Balleine et al. 1999).  
 
Figure 10. Estrogen signaling pathways. Estradiol (E2) passes the cell membrane and binds to 
its estrogen receptor (ER) in the nucleus. This is followed by formation of ER-homodimers, which 
function as transcription factors by binding to a specific target gene region, the estrogen 
responsive element (ERE), and starting with the transcription of genes like cyclin D1, 
progesterone receptor (PR), etc (1). Apart from its role as transcription factor, the E2-ER complex 
may also recruit other transcription factors (TF), thereby transactivating specific genes (2). In 
addition to E2, also growth factors (GF) may indirectly activate nuclear ER. GF bind to their 
membrane GF-receptors and activate protein-kinase cascades, leading to phosphorylation (P) 
and activation of nuclear ER (3). E2 may also bind to an estrogen binding site located in the cell 
membrane, leading to altered functions of cytoplasmic proteins followed by phosphorylation and 
activation of transcription factors (4). (Bjornstrom and Sjoberg 2005). 
 
E. Patient Age and Menopausal Status 
Other important parameters for the prognosis and selection of therapy are the 
age and menopausal status of the breast cancer patient. Several studies have shown 
that younger age (< 35) is associated with more aggressive tumors, a higher risk of 
relapse and a shorter overall survival (Schmidt et al. 2009). In particular, the 
menopausal stage influences the treatment strategy for hormone therapy. Since 
estrogen is primarily produced in the ovaries in premenopausal women, they receive 
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SERM together with ovarian suppressors. In postmenopausal patients, estrogens are 
mainly synthesized from androgens by the enzyme aromatase in the fatty tissue, and 
these patients are therefore treated with a combination of SERM with aromatase-
inhibitors.  
 
F. Human Epidermal Growth Factor Receptor 2 (HER2) 
HER2, also known as ErbB2 or Neu, is a membrane-spanning receptor tyrosine 
kinase, and is overexpressed in 20-30% of breast cancers (Harari and Yarden 2000). 
Upon stimulation, HER2 is recruited as co-receptor for other ErbB-receptors of the 
same family, and transduces its signals by subsequent autophosphorylation, which 
activates survival and mitogenic pathways such as ras-raf-MEK-Extracellular Signal 
Regulated Kinase (ERK) or phosphatidylinositol 3-kinase (PI3K)-Akt (Albanell et al. 
2003) (Figure 11). Overexpression of HER2 results either from gene amplification or 
mRNA overexpression and is associated with a higher probability of relapse and 
resistance to chemotherapy (Harari and Yarden 2000). Because of its prognostic role 
as well as its ability to predict response to antibodies (trastuzumab) or drugs 
(lapatinib, pazopanib) targeting the HER2 protein (Nanda 2007), breast tumors are 
routinely checked for overexpression or gene amplification of HER2. Three types of 
assays are currently used, namely IHC to measure the HER2 protein and 
fluorescence or chromogenic in situ hybridization (FISH or CISH) to detect HER2 
gene amplification. The in situ hybridization method applies dye-linked probes which 
specifically bind to the DNA sequences encoding for HER2, followed by detection via 
fluorescence or light microscopy. In routine, the HER2 status is mostly determined 
with a two-step method, with FISH or CISH used to confirm only moderate staining of 
IHC. All other cases are either negative (no or weak IHC staining) or positive (strong 
IHC staining) for HER2 (Cuadros and Villegas 2009). 
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Figure 11. HER2 signaling pathways. Upon binding of epidermal growth factor to the human 
epidermal growth factor receptors (HER) 1, 3 or 4, HER2 is recruited as co-receptor, followed by 
autophosphorylation (P) of the receptor dimer. The adaptor molecules src-homology-and-
collagen-containing-protein (shc) and growth-factor-receptor-bound (Grb) bind to the 
phosphorylated tyrosine residues of the receptor dimer and activate the protein son-of-sevenless 
(Sos), forming all together a multiprotein scaffold. This multiprotein scaffold alters the affinity of 
Ras for guanosine diphosphate which is exchanged by guanosine triphosphate, thereby 
activating Ras. Ras turns on mitogen-activated protein kinase kinases (MEK) to phosphorylate 
the extracellular-signal –regulated-kinase (ERK) or c-Jun-N-terminal-kinase (JNK), acting on the 
transcription factors activator-protein-1 (AP-1), sp-1 and nuclear-factor-kappa-B (NFκB) to start 
with the transcription of genes involved in cell proliferation and survival. Activated HER can also 
stimulate the phosphatidylinositol-3-kinase (PI3K), which phosphorylates inositol-containing lipids 
of the cell membrane. This recruits the protein-kinase-B (Akt) which phosphorylates numerous 
substrates, leading to activation of NFκB and transcription of antiapoptotic proteins. (Weinberg 
2007). 
 
 
 
 
 
 
 
 
24
3 INTRODUCTION  Prognostic and Predictive Markers 
 
The prognosis of patients with breast cancer is determined by a combination of 
the above described factors. In the St. Gallen Consensus Conference 2005, a panel 
of international breast cancer experts elaborated a novel stratification system with 
regard to the patient’s risk of local or distant recurrence. Based on data on patient 
age, tumor size, presence of tumor cells in local lymph nodes, tumor differentiation 
grade, HER2 status, and peritumoral vascular invasion, the patients are assigned to 
be at low, intermediate or high risk of local or distant recurrence (Table 2) 
(Goldhirsch et al. 2005). 
 
Low risk  Node negative AND all of the following features: 
Pathologic tumor size ≤2cm, AND 
Grade 1, AND 
Absence of peritumoral vascular invasion, AND  
HER2/neu gene neither overexpressed nor amplified, AND 
Age ≥35 years 
 
Node negative AND at least one of the following features:  
Pathologic tumor size >2cm, OR 
Grade 2-3, OR 
Presence of peritumoral vascular invasion, OR  
HER2/neu gene overexpressed or amplified, OR 
Age <35 years 
 
Intermediate risk  
Node positive (1-3 nodes involved) AND 
HER2/neu gene neither overexpressed nor amplified 
 
High risk  Node positive (1-3 nodes involved) AND 
HER2/neu gene overexpressed or amplified 
 
Node positive (4 or more involved nodes) 
Table 2. Prognosis of the likelihood to relapse for a patient with operated breast cancer. 
According to the St. Gallen expert meeting, the patients are assigned to risk categories depending 
on their age, tumor size and grade, spread of tumor cells to local lymph nodes or blood vessels 
and HER2 status (Goldhirsch et al. 2005). 
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3.2.2 Novel Strategies 
 
The exclusive assessment of already established prognostic factors sometimes 
fails to predict the course of disease. Moreover, the exact mechanisms involved in 
the initiation and progression of breast cancer have not yet been fully identified. 
Therefore, one of the challenges in tumor research is finding new biomarkers which 
should refine the prognosis of a patient’s particular course of disease, estimate his 
risk for recurrence and his chance of survival. Also, new biomarkers could play a role 
as target for novel drugs and could identify patient subgroups likely to benefit from a 
certain therapy.  
With respect to this thesis, two novel strategies are mentioned now, although 
their prognostic value and feasibility of assessment in routine diagnostics have to be 
further evaluated.  
 
A. Angiogenesis 
Tumor growth requires the delivery of oxygen and nutrients via blood vessels. 
Therefore, the formation of new blood vessels, termed angiogenesis, goes along with 
the growth of the tumor. Moreover, angiogenesis is associated with the spread of the 
tumor to distant organs, because the increase in the number of blood vessels in the 
tumor surrounding increases the chances for tumor cells to enter circulation.  
Hypoxic conditions in the tumor tissue prompt the tumor to secrete growth 
factors, like the vascular endothelial growth factor (VEGF), which stimulate the 
proliferation and motility of endothelial cells in the surrounding capillary network 
(Sessa et al. 2008; Phng and Gerhardt 2009). However, not all endothelial cells 
required for the new vessel originate from neighboring vessels, but also from the 
recruitment of circulating bone-marrow derived endothelial precursor cells (Sullivan et 
al. 2009).  
The angiogenic status of a tumor critically influences the patient’s survival and 
can be assessed by different approaches. The microvessel density has been shown 
to be a good estimate for the angiogenic status of the tumor and is assessed by IHC 
staining with antibodies directed against endothelial antigens (CD31, CD34, factor 
VIII related antigen) followed by manual or computer-based counting of the stained 
structures in relation to the tumor area under the microscope (Sullivan et al. 2009). 
According to recent studies, the microvessel density is associated with larger tumors, 
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presence of lymph node metastases, negative hormone receptor status and shorter 
survival of breast carcinoma patients (Mohammed et al. 2009; Sullivan et al. 2009). 
Besides their prognostic role, parameters describing neovascularization might also 
predict the response to antiangiogenic compounds (Sessa et al. 2008).  
 
B. Molecular Profiling 
The gene profile microarray technique permits the concomitant analysis of 
multiple genes thereby improving the molecular characterization and also the 
understanding of signaling pathways in breast cancer (Ramaswamy and Golub 
2002). This technique is based on the hybridization of prefabricated nucleic acid 
polymers, immobilized on a solid surface, with complementary gene sequences in 
the samples to be analyzed. In the two-color microarrays, the cDNAs of the sample 
and a reference sample are labeled with two different fluorescence dyes and then 
hybridized with the probes containing the respective sequence. Depending on the 
ratio of gene expression between sample and reference sample for a given gene, 
either none, one or both cDNAs are bound to their complementary probes, giving rise 
to different colors of varying intensity in the respective microarray spot. The 
fluorescence of these spots is measured, and the thus obtained data representing 
expression levels of thousands of genes are analyzed with a hierarchical clustering 
algorithm. Therefore, samples showing similarities in their overall gene expression 
are grouped together (Perou et al. 1999).  
According to their similar gene expression pattern, Perou et al defined four 
molecularly and clinically different breast cancer subtypes: luminal -, HER2-, normal 
breast- and basal-like (Perou et al. 2000). The study was performed on 36 infiltrating 
ductal and 2 lobular carcinomas, 1 ductal carcinoma in situ, 1 fibroadenoma (a 
benign breast lesion) and 3 normal breast samples. The gene expression patterns of 
these samples were compared to that of 11 cultured cell lines which served as 
reference, including cells derived from breast carcinoma, liposarcoma, T-cell 
leukemia, multiple myeloma and promyeloic leukemia, among others. Further 
examination of an extended data set showed that the luminal subgroup could be 
subclassified into luminal A- and luminal B-like cancers (Sorlie et al. 2001). The 
luminal subtypes make up 67% of all breast tumors, and are characterized by their 
expression patterns reminiscent of the luminal epithelial cells in the breast since they 
show high expression of ER-α and the cytokeratins (CK) 8 and 18, but a low 
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expression of HER2 (Perou et al. 2000). CK are intermediate filaments differentially 
expressed in epithelial cells dependent on the cell type and its differentiation status 
[reviewed by Quinlan et al 1985]. Compared to luminal A tumors, the luminal B 
subtype shows a higher expression of genes related to cell proliferation, like CCNB1, 
MKI67 and MYBL2 (Cheang et al. 2009). No expression of hormone receptors is 
seen in tumors of the HER2 subtype, which are characterized by overexpression of 
HER2 and frequent mutations (up to 80%) of the tumor suppressor p53. Moreover, 
high grade tumors show more likely features of the HER2- than the luminal subtype 
(Sorlie et al. 2001). The fibroadenoma together with the normal breast tissue 
specimens were clustered to the normal breast subtype. Tumors assigned to the 
normal breast subtype showed high expression of genes characteristic for adipose 
cells, like fatty-acid binding protein 4 or peroxisome proliferators-activated receptor 
gamma (PPAR-γ) (Sorlie et al. 2001). Basal-like tumors represented around 15% of 
the specimens analyzed, and show an expression pattern similar to myoepithelial 
cells of the normal breast, i.e. strong expression of the basal CK 5, 6 and 17, and 
lack of hormone receptor- and HER2-expression (Sotiriou et al. 2003). Interestingly, 
carriers of BRCA-1 mutations often develop carcinomas of the basal type (Turner et 
al. 2004). 
Importantly, this classification of tumors according to their gene expression 
profile, has been shown to be of clinical relevance as the five cancer subtypes, 
namely luminal A- and B-, HER2-, normal breast- and basal-like, significantly differ in 
their prognosis and therapy response, ranging from the best-prognosis luminal A- to 
the worst-prognosis basal-like tumors, which show a high propensity for brain 
metastases (Sorlie et al. 2001, Fadare and Tavassoli 2008).  
Since gene expression microarrays are expensive, a more convenient approach, 
namely IHC microarrays, has been developed. IHC microarrays are composed of 
paraffin-embedded tissue cores of about 0.6 mm in diameter spaced in an array 
pattern in a recipient paraffin block. From this block, sections are cut, mounted on 
adhesive slides, and each slide is subjected to immunohistochemical staining. 
Therefore, this technique allows the simultaneous analysis of many proteins (up to 
500, depending on the thickness of the sections) in a huge number of breast tumor 
samples, and according to the pattern of protein expression, in analogy to gene 
expression profiling, biologically distinct classes of breast cancer were defined (Abd 
El-Rehim et al. 2005). However, to date there is no international consensus on the 
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IHC definition of basal-like breast carcinomas since different studies have assessed 
different markers (Fadare and Tavassoli 2008). In most tissue microarray studies, 
tumors are classified as basal-like when being triple-negative for ER-, PR- and 
HER2, while showing immunostaining for the basal markers CK-5 and -6 and the 
epidermal growth factor receptor (EGFR) (Fadare and Tavassoli 2008). 
Histologically, basal like breast carcinomas mostly belong to invasive ductal or 
medullary tumors showing a high mitotic activity and therefore a high grade.  
To summarize, molecular profiling by gene expression and IHC microarray 
analysis can provide important information about key molecular events in breast 
cancer and may give a molecular explanation for the different histological phenotypes 
and their impact on the course of disease. Together with established markers, like 
ER, PR, HER2, tumor size, grade and lymph node stage, these techniques may thus 
permit a more accurate prediction of survival and also of therapy response (Hu et al. 
2006). 
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3.3 Cell Cycle Regulators – Impact on Proliferation 
 
Carcinogenesis and tumor growth are the result of uncontrolled cell division. 
Therefore, factors controlling the replication and division of a cell could be of 
relevance as novel biomarkers for breast cancer. 
 
The interval between two cell divisions, the cell cycle, is composed of four 
phases, the G1, S, G2 and M-phase. In the DNA synthesis (S)-phase, the cell 
duplicates its genetic information, and then divides in two in the mitosis (M)-phase. 
Two gap phases, G1 (between M and S) and G2 (between S and M) provide a safety 
gap before beginning with the next phase, allowing the cell to synthesize products 
necessary for the DNA-replication and to repair possible DNA-damages (reviewed by 
Blomen and Boonstra 2007). The correct progress of the cell cycle is controlled by a 
set of proteins, the cyclin-dependent protein kinases (CDK) and the cyclins, and 
feedback from downstream processes and the environment can hold these proteins 
off passing through checkpoints in the gap-phases and in the M-phase (reviewed by 
Malumbres and Barbacid 2009). If the cell fails to pass a checkpoint, cell cycle arrest 
is enforced. Notably, most signals resulting in cell cycle arrest act at the G1 
checkpoint, before entry into the S-phase. Cells then enter a resting state, G0 
(reviewed by Blomen and Boonstra 2007). Nine types of CDK-proteins, CDK 1 – 
CDK 9, and at least sixteen types of cyclins, cyclin A – cyclin T are known at present 
(reviewed by Blomen and Boonstra 2007). Different cyclin–CDK complexes are 
expressed in different phases of the cell cycle: cyclin D–CDK4/6 in G1; cyclin E–
CDK2 later in G1 and at the G1–S-phase transition; cyclin A–CDK2 during S, G2 and 
M phase; and cyclin B–CDK1/2 at the G2–M-phase transition (reviewed by Schwartz 
and Shah 2005).  
 
The orderly transition between the cell cycle phases depends on the CDK-
activity, which is regulated by several mechanisms, including activating and 
inactivating phosphorylations, binding to regulatory cyclin subunits, subcellular 
localization, and association with CDK inhibitors (CKI) as well as controlled 
degradation of regulatory subunits (reviewed by Lolli and Johnson 2005). 
The cyclin-CDK-complex is a substrate for two protein kinases: the activating 
kinase MO15 (CDK7), which introduces a phosphate residue in the activating site of 
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the CDK molecule, and the inhibitory Wee1-protein, which phosphorylates a tyrosine 
residue close to the catalytic site of CDK, thereby decreasing the CDK-cyclin activity. 
This inhibitory phosphate group is then removed from the tyrosine residue by the 
phosphatase CDC25 (Figure 12) (Parker and Piwnica-Worms 1992; Shuttleworth 
1995; Kellogg 2003).  
 
 
 
Figure 12. Progression through the cell division cycle is tightly controlled by complexes of cyclin 
dependent kinases (CDK) with cyclins. The activity of these complexes is regulated via 
phosphorylation by three different enzymes. First, the CDK-cyclin complex becomes a substrate 
for the kinase MO15, which introduces a phosphate residue on the activating site of the complex. 
In parallel, the kinase Wee1 decreases the activity of the CDK-cyclin complex by phosphorylating 
its catalytic site. This inhibitory phosphate residue is removed by the phosphatase CDC25A, 
thereby activating the CDK-cyclin complex. (Alberts et al 1994) 
 
Three different CDC25 types, A, B and C, have been found in mammalian cells. 
The CDC25 subtypes are expressed and activated at different times during the cell 
cycle and have been shown to interact with different cyclin – CDK - complexes. 
CDC25A expression is required for S-phase entry and is induced in G1 by the 
transcription factors c-Myc and E2F, while CDC25B and CDC25C act primarily at the 
G2/M transition (reviewed by Kiyokawa and Ray 2008). 
In a final step, the CDK-cyclin-complex adopts its correct conformation through 
another phosphorylation in its activation segment by the CDK-activating kinase, 
which is composed of cyclin H, MO15 and Mat1 (reviewed by Lolli and Johnson 
2005). 
 
CDK inhibitory proteins (CKI) belong to two families, which differ in their structure 
and CDK specificity. The first family, known as Cip/Kip (kinase inhibitor protein) 
family, comprises p21waf1/cip1, p27Kip1 and p57Kip2, which can bind to all G1-cyclin/CDK 
complexes, though having a preference for CDK2. The second group includes the 
INK4 proteins (inhibitors of CDK4) p16INK4a, p15INK4b, p18INK4c and p19INK4d, so-
named because they specifically inhibit CDK4 and CDK6 (reviewed by Coqueret 
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2003). CKIs play an important role in the response of cells to growth-inhibitory 
signals, like induction of differentiation, p53 activation after DNA damage, contact-
inhibition, senescence, etc. As expected from their capacity to block the progression 
of the cell cycle, CKIs are often inactivated in cancer (reviewed by Canepa et al. 
2007). 
 
As described above, checkpoints in the different phases of the cell cycle ensure 
the correct transcription of the genetic information. The first checkpoint to be passed 
through in G1 is set by the retinoblastoma (Rb) tumor suppressor which, in its active, 
hypophosphorylated, state, forms inhibitory complexes with E2F-DP transcription 
factors, required for the start of the S-phase (reviewed by Schwartz and Shah 2005). 
Mitogens upregulate the expression of cyclin D which binds to CDK4 and CDK6 and 
activates them (reviewed by Blomen and Boonstra 2007). Increasing levels of cyclin 
D lead to the release of CDKs from their inhibitory complexes with Cip/Kip CKIs, and 
activation of the cyclin D-CDK4/6 pathway. Activated cyclin D-CDK4/6 partially 
phosphorylate and inactivate the Rb-protein, thereby releasing the E2F transcription 
factors, which can start with the transcription of genes, like cyclin E (Figure 13) 
(reviewed by Schwartz and Shah 2005). Cyclin E forms an active complex with CDK2 
which completely hyperphosphorylates and inactivates Rb, thereby releasing and 
activating the E2F transcription factors. E2F now starts with the transcription of 
numerous S-phase proteins, like dihydrofolate-reductase, thymidine kinase, 
thymidylate synthase, DNA polymerase-α, CDK1, cyclin A, and E2F-1 itself (Dirks et 
al. 1998). At the same time, cyclin E-CDK2 phosphorylates and inactivates p27KIP1, 
thereby counteracting the inhibitory influence of p27KIP1 on cyclin A-CDK2 and 
allowing cyclin A-CDK2 to start the S phase (Muller et al. 1997). At this so-called 
restriction point, the cell cycle progresses independently of external stimuli, like 
growth factors, chemicals or metabolites. Remarkably, in tumors, characterized by 
their autonomous growth, this restriction point is frequently inactivated (reviewed by 
Malumbres and Barbacid 2009).  
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Figure 13. Molecular interplays at the transition from G1- to DNA-Synthesis (S) - phase of the cell 
cycle. In early G1, mitogens stimulate the formation of complexes of cyclin-dependent kinase 4 or 
6 (CDK4/6) with cyclin D. The activity of this complex is negatively regulated by cyclin-
dependent-kinase-inhibitory proteins (Cip). However, when a threshold level of cyclin D is 
reached, the CDK4/6-cyclin D- complex is not longer sequestered by Cip and can enhance the 
phosphorylation and thus inactivation of retinoblastoma protein (Rb), which thereby increasingly 
releases the E2F transcription factors. E2F starts with the transcription of cyclin E, which 
associates with CDK2 to an active complex. This complex is negatively regulated by two classes 
of CDK-inhibitors, the Cip and the inhibitors of CDK4 (INK4). Increasing levels of CDK2-cyclin E- 
complexes then completely hyperphosphorylate Rb resulting in total release of E2F and the 
passage through the G1-S-restriction point. From now on, cell cycle progression is independent 
of external mitogenic stimuli. (Kolch et al. 2002), modified. 
 
The Rb pathway is also connected with another major tumor suppressor, p53. 
The p53 protein is short-lived, because an associated protein, Mdm2, induces its 
ubiquitination and degradation (reviewed by Soussi and Beroud 2001). Genetic 
damage results in the stabilization of p53 which thereupon triggers apoptosis or cell-
cycle arrest by upregulation of the cyclin E-CDK-inhibitor p21waf1/cip1 (reviewed by 
Kolch et al. 2002).  
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Remarkably, p53 upregulates its inhibitor Mdm2, creating a self-regulatory 
feedback loop that keeps the levels of p53 and Mdm2 in balance. The interaction 
between p53 and Mdm2 is counteracted by the protein ARF, thereby increasing the 
levels and stability of p53 (Figure 14) (reviewed by Soussi and Beroud 2001). ARF is 
an abbreviation for “alternative reading frame”, because it is encoded by the same 
genetic locus as the CKI p16INK4, but is transcribed from a different promoter 
(reviewed by Gil and Peters 2006). Interestingly, ARF transcription is induced by E2F 
released from Rb (reviewed by Kolch et al. 2002). Therefore, it depends on the ratio 
of ARF to Mdm2 whether the cell passes the restriction point or not. Increased 
stabilization of p53 by ARF induces p21waf/cip, which, via interaction with CDK2, 
prevents the inactivation of Rb by CDK2 thereby halting the cell at the G1–S-phase 
boundary (reviewed by Soussi and Beroud 2001). Vice versa, the degradation of p53 
enables the cell to overcome the restriction point. Therefore, loss or inactivation of 
the ARF- p16INK4 gene affects both tumor suppressors, the Rb and p53 pathway 
(reviewed by Kolch et al. 2002). 
 
In addition to its role in G1 arrest, p53 also enforces cell cycle arrest in other 
phases of the cell cycle, like in G2. Moreover, p53 plays an important role in DNA 
repair and senescence, where the cell can no longer enter the cell cycle and looses 
its ability to divide (reviewed by Blomen and Boonstra 2007). 
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Figure 14. p53 pathway. Mitogenic hyperactivation results in stabilization of p53, which 
thereupon induces apoptosis or prevents cell cycle progression by upregulating the cyclin 
dependent kinase inhibitor p21waf1/cip1. p53 is stabilized by ARF which prevents the interaction 
between p53 and its inhibitor Mdm2. Binding of Mdm2 to p53 increases the susceptibility of p53 
to get ubiquitinylated (Ub) and degraded. ARF transcription is induced by E2F transcription 
factors, which are released when the retinoblastoma protein (Rb) is hyperphosphorylated (pRb). 
Interestingly, ARF is encoded by the same genetic locus as p16INK4, which contributes to cell 
cycle arrest by inhibiting the activity of cyclin E-CDK2. (Soussi and Beroud 2001; Gil and Peters 
2006). 
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3.4 Melatonin and Melatonin Receptors - Role in Cancer Development 
and Progression 
 
3.4.1 Melatonin and its Actions on the Molecular Level 
 
Melatonin, N-acetyl-5-methoxytryptamine, is a lipophilic hormone which is mainly 
produced and excreted in the pineal gland in a circadian rhythm during the night. The 
synthesis of melatonin from tryptophan in the pineal gland is controlled by the 
hypothalamic suprachiasmatic nucleus, which receives information from the retina on 
the environmental lightness (reviewed by Pandi-Perumal et al. 2008).  
 
Because pineal melatonin production occurs during the dark and is suppressed 
by light and because melatonin is quickly removed from the circulation (half life 
approximately 30 min) (Brown et al. 1997), the time and duration of the melatonin 
peak reflects the environmental night period. Thus, melatonin is regarded a 
neuroendocrine mediator of the photoperiod (reviewed by Pandi-Perumal et al. 
2008).  
 
Besides its production in the pineal gland, synthesis of melatonin has been 
demonstrated in retina, gut, skin, bone marrow and lymphocytes, although these 
sites are only of local relevance because they do not influence the blood levels 
(Pandi-Perumal et al. 2008).  
 
Many functions of melatonin in the body have been described, although its most 
important encompasses the regulation of circadian and seasonal rhythms. Melatonin 
reduces the plasma levels of gonadal estrogens via interaction with the hypothalamic 
pituitary axis (Cos et al. 2008). Other reported actions of melatonin include its 
involvement in the sleep-wake rhythm, aging process, bone metabolism, renal 
function, blood pressure control and regulation of the immune response (Brzezinski 
1997; Ekmekcioglu 2006; Reiter et al. 2007).  
 
These multiple effects of melatonin result from its action as free radical scavenger 
and its binding to membrane and nuclear receptors (Figure 15) (Reiter et al. 2007). 
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Figure 15. Sites of melatonin action at the cellular level. Binding of melatonin (Mel) to its 7-
transmembrane MT1 or MT2 receptor leads to the cleavage of the α-subunit (Gi α) from the 
Gi protein linked to the receptor. This results in inhibition of adenylate cyclase activity and 
thus in decreased levels of cyclic adenosine monophosphate (cAMP) which is responsible for 
the phosphorylation and binding of the transcription factor cAMP response element binding 
protein (CREB) to its cAMP response element (CRE) in DNA (1). Due to its lipophilicity, 
melatonin passes the cell membrane easily. It prevents the formation of free radicals via 
interaction with MT3, a quinone reductase (2) and acts as scavenger of radicals (3). Other 
intracellular binding sites for melatonin include Ca2+-calmodulin (4) and the nuclear receptors 
retinoid Z receptor (RZR) and retinoid orphan receptor (ROR). Upon activation by melatonin, 
RZR/ROR monomers bind to their RORα-response element (RORE) in DNA and start with 
gene expression (5). (Brzezinski 1997, modified). 
 
A. Antioxidative Effects 
Melatonin and its metabolites reduce oxidative damage by preventing the 
formation of free radicals and enhancing ATP production in the mitochondria which is 
required for the repair of cellular damage. Moreover, melatonin scavenges already 
formed free radicals (reviewed by Reiter et al. 2007). 
 
B. Action through Membrane Receptors 
Many effects of melatonin are mediated via its binding to its high-affinity seven-
transmembrane receptors, MT1 and MT2. Due to their high homology at the amino 
acid level (about 55% overall and 70% within transmembrane domains), MT1 and 
MT2 form their own family which is part of the superfamily of G-protein coupled 
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receptors (GPCR) (reviewed by Jockers et al. 2008). Recently, another member of 
the melatonin receptor family, namely the melatonin related receptor GPR50, has 
been identified in human brain and peripheral tissues. However, this receptor is 
incapable of melatonin binding, and its natural ligand has not yet been identified 
(reviewed by Jockers et al. 2008). Also, MT1 and MT2 slightly differ in their affinity for 
melatonin, being lower for MT2. Melatonin binding and receptor mRNA levels 
underlie a circadian rhythm, and the expression levels of the receptor depend on the 
plasma melatonin concentration (reviewed by Pandi-Perumal et al. 2008).  
Depending on the cellular context, diverse signaling cascades triggered by MT1 
or MT2 are possible, involving in most cases the activation of both, pertussis toxin-
sensitive Gi and –insensitive Gq/11 proteins that mediate the blockade of adenylate 
cyclase or the activation of phospholipase C-β (PLC-β). The inhibition of adenylate 
cyclase results in decreased levels of cyclic adenosine monophosphate (cAMP), in 
reduced activity of protein kinase A (PKA) and decreased phosphorylation of the 
nuclear transcription factor cAMP-responsive element binding protein (CREB) which 
is important for cAMP regulated gene expression and proliferation. On the other 
hand, the activation of PLC-β by the βγ-subunit of the G protein or by Gαq results in 
increased phosphorylation of the mitogen activated protein kinases (MAPK) MEK, 
ERK and JNK which activate transcription factors important for protein synthesis, cell 
growth, survival and motility (Figure 16) (reviewed by Wilkinson and Millar 2000; Lee 
et al. 2001; Goldsmith and Dhanasekaran 2007; Jockers et al. 2008). MT1 can also 
regulate ion channels, like large conductance calcium activated potassium channels 
or inward rectifier potassium channels (reviewed by Pandi-Perumal et al. 2008). 
Moreover, studies have shown that MT1, MT2 and GPR50 can form heterodimers 
which might also influence receptor signaling and trafficking (reviewed by Jockers et 
al. 2008). Therefore, MT receptors might use many diverse signaling pathways 
leading either to pro-differentiating or proliferative effects.  
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Figure 16. Overview on MT1-signaling pathways, according to: (Dubocovich and Masana 
2003a, Jockers et al. 2008). MT1 is a seven-transmembrane receptor which couples to Gi or 
Gq proteins. Upon activation of the receptor, the heterotrimeric G-protein detaches and 
dissociates into its Gα- and Gβγ- subunits. This leads to activation of several downstream 
signaling cascades: 1) Giα decreases the levels of cyclic adenosine monophosphate (cAMP), 
thereby decreasing the activity of protein kinase A (PKA) on the phosphorylation of cAMP 
response element binding protein (CREB), a transcription factor which interacts with other 
transcription factors (TF), 2) phospholipase C-β (PLC-β) is activated by the βγ-subunits of Gi or 
Gq or by Gqα. As consequence, the levels of inositol-triphosphate (IP3), and calcium-
calmodulin (CaM) increase, leading to activation of the mitogen activated protein kinases MEK, 
ERK and JNK. Moreover, activation of PLC-β enhances the levels of diacylglycerol (DAG) and 
calcium which then lead to activation of protein kinase C (PKC). All mentioned signaling 
pathways influence diverse transcription factors (TF) and thereby the expression of genes 
involved in such different cell responses as differentiation, proliferation, cell survival, migration 
or angiogenesis. 
 
MT1 and MT2 are expressed singly or together mainly in the central nervous 
system but also in many other sites in the body.  
In the periphery, MT1 has been identified in the retina, coronary blood vessels 
and aorta, mammary gland epithelium, gastrointestinal tract, pancreas, gallbladder, 
liver, kidney, bladder, ovary, testis, prostate, skin, bone and in immune cells 
(reviewed by Ekmekcioglu 2006).  
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By contrast, MT2 is more restricted to the brain, but has been also found in lung, 
cardiac, aortic and coronary tissue, myometrium, immune cells, duodenum and 
adipocytes (reviewed by Ekmekcioglu 2006).  
 
C. Action through Nuclear Receptors 
In addition to its membrane receptors, melatonin acts also on related orphan 
receptors, located in the nucleus. These receptors belong to the RZR/ROR receptor 
subfamily, which includes three subtypes (α, β, γ) and four splicing variants of the α-
subtype (RORα1, RORα2, RORα3, RZRα) (reviewed by Smirnov 2001). RZR/RORα 
is expressed in various organs, whereas RZRβ is specific for brain and retina 
(reviewed by Smirnov 2001). RORγ was identified in skeletal muscle, liver, kidney 
and adipocytes (reviewed by Smirnov 2001). Signaling through these receptors has 
been associated with the action of melatonin on immune cells and also with its 
activation of antioxidative enzymes (reviewed by Reiter et al. 2007).  
 
D. Other intracellular Binding Sites for Melatonin 
Melatonin interacts with intracellular molecules, like calmodulin, calreticulin and 
tubulin. Moreover, it was shown to prevent the formation of free radicals through its 
action on MT3, a quinone reductase (reviewed by Jockers et al. 2008; Pandi-Perumal 
et al. 2008).  
 
 
3.4.2 Melatonin, MT1 and their Role in Breast Cancer 
 
A. Evidence for a Role of Melatonin in Breast Cancer 
It is well documented that melatonin plays a role in the initiation and progression 
of cancer. For example, women being constantly exposed to light at night, e.g. due to 
shift work, had an increased incidence of breast cancer which was accompanied by 
decreased urinary levels of melatonin and its metabolites (Schernhammer and 
Schulmeister 2004). Moreover, it was shown that this reduction in melatonin plasma 
and urinary levels was negatively associated with the ER-status (Tamarkin et al. 
1982; Danforth et al. 1985; Bartsch et al. 1991). Further studies found an inverse 
relationship between nocturnal melatonin serum levels and the size of the primary 
breast tumor, and melatonin levels in breast cancer tissue correlated negatively with 
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the tumor differentiation grade (Bartsch et al. 1989; Maestroni and Conti 1996). In 
accordance with these investigations, studies conducted in animals showed that 
pinealectomy stimulates whereas melatonin administration inhibits tumor formation in 
rats treated with carcinogens (reviewed by Srinivasan et al. 2008). 
 
B. Molecular Actions of Melatonin on Breast Cancer Cells 
The oncostatic effect of melatonin on breast cancer results from its action as 
radical scavenger accompanied by activation of its membrane (MT1) and nuclear 
receptors (Ram et al. 2002; Grant et al. 2009).  
Expression of MT1, but not of MT2, is found in human breast cancer cell lines 
and also in normal and malignant human breast tissue (Dillon et al. 2002; Lai et al. 
2008).  
Overexpression of MT1 significantly inhibited the proliferation of ER-positive MCF 
7-cells, which were originally isolated from the pleural effusion of a woman with 
metastatic breast cancer (Yuan et al. 2002). Moreover, breast cancer cell lines have 
been shown to express nuclear RZR/RORα receptors, and high doses of the 
RZR/RORα agonist CGP-52608 were lethal for MCF-7 cells (Ram et al. 2002). Other 
oncostatic mechanisms of melatonin include its stimulating effect on immune cells 
and its anti-invasive and anti-metastatic actions (Table 3). 
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Effect Suggested Mechanism References 
inhibition of cyclin D1, increase in expression of p53 and 
p21waf1/cip1 
(Mediavilla et al. 1999; 
Cini et al. 2005)  
increase of degradation of calmodulin which is involved in 
the initiation of S- and M-phase of the cell cycle (Blask et al. 2002)  
decrease in uptake of linoleic acid leads to decreased 
formation of 13-OH-Octadienoic Acid, which increases 
proliferation through activation of epidermal growth factor 
signaling 
(Blask et al. 2004) 
increase in number of gap junctions leads to decreased 
proliferation rate 
(Cos and Fernandez 
2000)  
inhibition of telomerase activity which is important for cell 
survival 
(Leon-Blanco et al. 
2003)  
disruption of mitochondrial respiration and induction of 
apoptosis (Scott et al. 2001)  
Inhibition of Proliferation 
and Induction of Apoptosis 
of Tumor Cells 
melatonin interacts with the tumor cell estrogen 
responsive pathway. It decreases i) circulating levels of 
gonadal estrogens via interaction with the hypothalamic 
pituitary axis, ii) the expression of ER-α and iii) the 
binding of the estradiol-ER complex to DNA, thereby 
preventing the transcription of ER regulated genes, e.g. 
of PR and cyclin D1. Moreover, melatonin downregulates 
the expression of genes responsible for the local 
synthesis or activation of estrogen 
(Sanchez-Barcelo et al. 
2003; Korkmaz et al. 
2008) 
   
inhibition of the synthesis of endothelin 1 which is 
implicated in cell proliferation and neoangiogenesis (Reiter 2004)  
Reduction of Vascular 
Growth 
melatonin induces apoptosis of human umbilical vein 
endothelial cells  (Cui et al. 2006)  
   
increase in expression of E-cadherin and β1-integrin (Cos et al. 1998)  
Inhibition of Invasion and 
Metastasis 
melatonin induces a rearrangement of microfilaments 
and microtubules (Ortiz-Lopez et al. 2009) 
   
increase in the activity of T- and B-lymphocytes, 
monocytes and natural killer cells (Maestroni 1999)  
Immunoenhancement 
augmentation of secretion of cytokines, like interleukin-2, 
-6, -12 and interferon-γ (Maestroni 1999) 
   
Reduction of Oxidative 
Stress 
melatonin acts as radical scavenger and reduces DNA 
damage (Reiter et al. 1999) 
Table 3. Mechanisms by which melatonin suppresses breast cancer proliferation. 
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Although studies on breast cancer cells in culture clearly showed an 
antiproliferative effect of melatonin via its interaction with MT1, a recent IHC study 
found higher MT1 levels in the tumor than in normal breast tissue (Dillon et al. 2002). 
Moreover, higher MT1 levels in the cancer specimens were significantly positively 
related to the tumor differentiation grade (Dillon et al. 2002). Interestingly, previous 
studies demonstrated that MT1 might be spontaneously active also in the absence of 
agonists and that this constitutive activity even occurs when the receptor is not 
experimentally overexpressed (Roka et al. 1999; Jockers et al. 2008). Since 
activation of MT1 may induce many different signaling cascades leading either to 
differentiation or proliferation (see chapter 3.4.1 and Figure 16), other functions of 
MT1 than those observed in cell culture seem therefore to be likely in breast cancer 
tissue.  
 
3.4.3 Melatonin and Cell Cycle 
 
The effects of melatonin on the cell cycle of breast cancer cells are associated 
with its inhibition of estrogen-induced cell proliferation.  
 
Upon activation by estradiol, the estradiol-ER-α complex binds to their estrogen 
response element (ERE) in DNA and starts with the transcription of genes implicated 
in cell proliferation, like c-myc (reviewed by Renoir et al. 2008). The transcription 
factor c-myc itself then initiates the transcription of genes encoding for cell cycle 
regulators, such as cyclin D1 (reviewed by Butt et al. 2005). In addition to this indirect 
effect on cyclin D1 transcription, the estrogen-ER-α complex has been shown also to 
bind directly to a cAMP response element (CRE) on the cyclin D1 promoter, thereby 
upregulating cyclin D1 expression (reviewed by Renoir et al. 2008). Besides its direct 
action as transcription factor, ER-α regulates gene-expression via its binding to other 
transcription factors, like the Fos/Jun activating protein -1 complex (reviewed by Butt 
et al. 2005).  
 
Melatonin abolishes these cell cycle promoting effects of estrogen signaling 
through multiple mechanisms. First, it reduces the levels of circulating estrogens, 
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and, second, it decreases the expression of ER-α (reviewed by Sanchez-Barcelo et 
al. 2005). Moreover, melatonin blocks the binding of estradiol-ER-α complexes to 
DNA and it also decreases the transcriptional activity of ER-α (reviewed by Sanchez-
Barcelo et al. 2005). These effects were found to be mediated via MT1 (reviewed by 
Sanchez-Barcelo et al. 2005). Recently, melatonin was shown to inhibit the estradiol-
induced upregulation of cyclin D1 transcription via interaction with the transcription 
factors ATF-2 and c-jun which bind to the cAMP response element in the cyclin D1 
promoter (Cini et al. 2005). 
Another mechanism through which melatonin delays cell cycle progression 
comprises the induction of p53 and p21waf1 – expression (Cos et al. 2002). Moreover, 
a recent study showed that activation of MT1 by melatonin induces apoptosis which 
was associated with an increase in p53- but a decrease in Mdm2- levels (Cucina et 
al. 2008).  
 
3.4.4 Melatonin and Cancer Stem Cells 
 
A. Stem Cells and Cancer Stem Cells in the Breast 
Adult stem/progenitor cells are a small dormant, long-lived and self-renewing 
population throughout the body, which have the capacity to differentiate into more 
specialized cell types (reviewed by Woodward et al. 2005). Depending on their 
differentiation potential, they may mature into cell types from all three germ layers 
(pluripotent), into several cells originating from one germ layer (multipotent) or only 
into one specialized cell type (unipotent) (reviewed by Wiese et al. 2004). It is 
thought that signals from the local environment (e.g. interaction of adhesion 
molecules with the extracellular matrix) maintain the stem cells in their quiescent and 
undifferentiated status, in the so called stem cell niche (reviewed by Woodward et al. 
2005). When necessary, the stem cells proliferate to generate an exact copy of 
themselves (selfrenewal), thereby maintaining the stem cell pool, or they differentiate 
into cells with a limited self-renewal capacity or even a fully differentiated mature cell. 
This process is especially important after injury processes when the tissue has to be 
reconstituted. Progenitors may not only be restricted to one tissue but can also 
migrate to and settle down in other tissues, e.g. hematopoetic progenitors in skeletal 
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muscle or neuronal stem cells in the mammary gland (Asahara et al. 1997; Kawada 
and Ogawa 2001; Booth et al 2008).  
In the mammary gland, stem cells are responsible for the rapid growth of the 
breast during puberty, but also for the changes during pregnancy and lactation 
(reviewed by Woodward et al. 2005). The presence of stem cells in breast tissue has 
been experimentally demonstrated by injection of breast progenitor cells, as defined 
by their capacity to efflux the dye Hoechst 33342, into cleared mammary fat pads of 
recipient mice which then developed intact and functional breast glands (Alvi et al. 
2003). 
 
During their long life-span, stem cells might accumulate mutations, giving rise to 
formation of cancer stem cells (reviewed by Yehiely et al. 2006). Indeed, there is 
increasing evidence that some cancers might be derived from stem cells. For 
example, molecular pathways involved in stem cell renewal, like Wnt, Notch, PTEN, 
are often deregulated in a number of tumors (reviewed by Ponti et al. 2006). Also, 
tumor cells show often similar properties like normal stem cells, e.g. low 
differentiation, self-renewal, migration and cytoprotection (e.g. overexpression of anti-
apoptotic proteins, and overexpression of drug efflux pumps) (reviewed by Ponti et 
al. 2006). Tumor-initiating cancer stem cells were found in many hematological and 
solid malignancies, like breast cancer (reviewed by Gonzalez-Sarmiento and Perez-
Losada 2008). Al-Haji and coworkers showed that a few hundreds of cells isolated 
from breast cancer patients and transplanted into mammary fat pads of 
immunodeficient mice could reconstitute the tumor from which they were derived (Al-
Hajj et al. 2003). Remarkably, only tumor cells with high expression of the cell 
surface antigen CD44, together with no or low expression of CD24 showed this 
tumor-initiating potential. In an in vitro experiment performed by another group, 
CD44+CD24- human breast cancer cells formed non-adherent spherical cell clusters, 
mammospheres, a property described previously only for normal mammary 
progenitors (Ponti et al. 2005). Interestingly, it has been suggested that the different 
molecular subtypes of breast cancer, like luminal-, HER2- or basal-like, might 
originate from breast progenitor cells at distinct stages of lineage differentiation, with 
luminal-like breast tumors arising from more differentiated cells and basal–like 
carcinomas from the most primitive stem cells (reviewed by Birnbaum et al. 2004). 
This is further supported by the fact, that basal-like breast carcinomas and mammary 
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stem cells show similar protein expression profiles, e.g. CK5, CK14, α6-integrin, 
vimentin and αB-crystallin (reviewed by Yehiely et al. 2006). With respect to their 
cytoprotective mechanisms and their capacity for self-renewal and unlimited 
proliferation, cancer stem cells have a crucial impact on the patient’s further course 
of disease. Tumor stem cells might be resistant to established cytostatic therapy due 
to their low cell cycle kinetics, activation of DNA damage repair mechanisms, and 
their upregulation of drug efflux pumps (multidrug resistance transporter 1, MDR1; 
breast cancer resistance protein, BCRP) expelling chemotherapeutic agents out of 
the cancer cell, and may therefore survive and reconstitute the tumor, leading to 
cancer recurrence (reviewed by Eyler and Rich 2008).  
 
B. Nestin – a Novel Marker for Cancer Stem Cells? 
Nestin is a type VI intermediate filament protein of 240 kDa, which was first 
identified in neuroepithelial stem cells (reviewed by Wiese et al. 2004). Intermediate 
filaments are polymeric components of the cytoskeleton and play also an important 
role in cell adhesion (reviewed by Omary et al. 2004). Like other intermediate 
filament proteins, the structure of nestin is composed of an α-helical central rod 
domain, but in contrast to the other intermediate filament proteins, the N-terminus is 
very short which makes it impossible for nestin to self-assemble. Therefore, nestin 
assembles with other intermediate filament proteins, like vimentin or desmin, or with 
microfilaments and microtubules via its long C-terminus (reviewed by Wiese et al. 
2004).  
 
Nestin is expressed by many cell types during development, but is downregulated 
upon differentiation. In differentiated cells it is replaced by other intermediate filament 
proteins such as glial acidic protein in astrocytes or desmin in muscle cells 
(Michalczyk and Ziman 2005). Nestin is highly expressed during early neurogenesis 
but is also found in proliferating and migrating cells in a variety of other fetal and 
embryonic tissues (reviewed by Wiese et al. 2004).  
In adults, nestin-expressing cells are restricted to defined locations, where they 
may function as cellular reserve. These nestin-expressing cells have been found in 
the dermis, hair follicles, intestine, pancreas, bone marrow, testis, vascular 
endothelium, brain, central and peripheric nerve system, retina, heart, muscle and 
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other tissues, and  show characteristic features of progenitor cells, such as 
multipotency, infinite proliferation, and self-renewal capacity (reviewed by Wiese et 
al. 2004; Kolar et al. 2007). Remarkably, expression of nestin is also found in 
myoepithelial cells lining the milk ducts in healthy breast tissue (Kolar et al. 2007). In 
premalignant lesions of the breast, like ductal or lobular carcinoma in situ, the nestin 
expression of myoepithelial cells persists, but is lost when the myoepithelial cells 
disappear and tumors become invasive (Kolar et al. 2007).  
Concordant with the expression of nestin in progenitors, nestin is upregulated 
after tissue injury, e.g. in infarcted myocardium (Scobioala et al. 2008). The exact 
mechanisms or factors which regulate nestin expression are still unclear.  
 
Nestin expression was also observed under malignant conditions in a cell 
population with characteristics of cancer stem cells which could differentiate into 
both, epithelial and endothelial cells (Bussolati et al. 2008). As already mentioned in 
chapter 3.4.A, breast carcinomas of the basal subtype show a transcriptional profile 
resembling that of mammary stem cells (Yehiely et al. 2006). In this regard, 
immunostaining of nestin was shown in tumor cells infiltrating the stroma of breast 
cancers of the ER-, PR-, HER2-triple negative (basal-like) subtype (Li et al. 2007; 
Parry et al. 2008). Moreover, in the study of Parry and coworkers, nestin expression 
was exclusively found in high grade, G3, tumors (Parry et al. 2008). 
A correlation of nestin expression with dedifferentiation and tumor grade has 
been shown also for other tumors, e.g. of the central nervous system (Strojnik et al. 
2007). Moreover, previous studies on U-373 MG human glioblastoma cells and on 
human prostate carcinoma cells showed an association between nestin expression 
and changes in cell shape and increased motility (Zhou and Skalli 2000; Kleeberger 
et al. 2007). Also, nestin is expressed in mitotically active cells, indicating a complex 
role for nestin in the regulation of intermediate filament assembly and thus in cell 
remodeling (Michalczyk and Ziman 2005).  
Apart from breast cancer, upregulation of nestin expression has been found in 
many other tumors, e.g. melanoma, rhabdomyosarcoma, gastrointestinal stromal 
tumors, pancreatic adenocarcinoma, angiosarcoma, testicular stromal tumors and 
adrenocortical tumors (Kobayashi et al. 1998; Tsujimura et al. 2001; Lobo et al. 2004; 
Ackermann et al. 2005; Toti et al. 2005; Yang et al. 2008; Murphy et al. 2009). In 
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hormone independent prostate cancer, nestin expression was associated with 
formation of metastases and poor patient survival (Kleeberger et al. 2007).  
Besides its expression in cancer stem cells, in neoplasias, nestin is also found in 
endothelial cells of newly formed small blood vessels (Mokry et al. 2004). Bussolati et 
al showed that nestin-expressing breast cancer progenitors might not only 
differentiate into epithelial but also into vascular endothelial cells leading to formation 
of capillaries (Bussolati et al. 2008). As already mentioned in chapter 3.2.2, 
angiogenesis is an important factor in the proliferation and metastasis of neoplasms. 
Indeed, a strong immunohistochemical staining of nestin was found in the capillary 
endothelium in breast tumors (Kolar et al. 2007). 
 
C. Melatonin and MT1 -  Impact on Stem Cells 
The expression of MT1, together with nestin, in the murine neural stem cell line 
C17.2 was recently reported (Niles et al. 2004). Neural stem cells are multipotent 
which means that they can differentiate into several types of neural cells, like 
neurons, astrocytes or oligodendrocytes. Of special interest for this thesis, another 
study showed that neural stem cells can migrate to and reside in a new 
microenvironment and can take over the function of mammary progenitors (Booth et 
al. 2008). Moreover, in C17.2 neuronal stem cells, it was found that activation of MT1 
by melatonin induces the expression of the glial cell-line derived neurotrophic factor 
(GDNF), and that this effect can be inhibited by the adenylate cyclase activator 
forskolin, followed by induction of differentiation processes (Niles et al. 2004). GDNF 
enhances proliferation, survival and migration of neurons in brain, spinal cord and 
periphery via its binding to glycosyl phosphatidylinositol-linked GDNF family receptor-
α (GFR-α), which recruits the receptor tyrosine kinase RET (Esseghir et al. 2007). 
Remarkably, a recent study showed the expression of GDNF, RET and GFR-α also 
in breast cancer specimens, and high GFR-α-mRNA levels were associated with 
lymphovascular invasion and lymph node metastasis (Esseghir et al. 2007). Taken 
together, melatonin might induce proliferation and/or enhance survival of progenitors 
or already differentiated cells through upregulation of GDNF expression in (neuronal) 
stem cells expressing MT1. This might be of relevance in breast carcinogenesis 
since neural stem cells may settle down also in peripheral tissues like the breast.  
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3.4.5 Metabolism of Melatonin 
The efficacy of melatonin’s action is limited by metabolizing enzymes which 
decrease the required intracellular concentration of melatonin.  
 
A. Hepatic Metabolism 
Upon release into the blood stream, melatonin is rapidly cleared in a single 
passage through the liver, where it is mainly metabolized to 6-OH-melatonin by the 
cytochrome P450 enzymes (CYP) 1A2, 1A1 and, to a minor extent, also by 
CYP2C19 (Ma et al. 2005). Around 70% of 6-OH-melatonin is then conjugated with 
sulfate residues while only 6% is glucuronidated (Cardinali 1981). This conjugation 
reaction enhances the substrate’s hydrophilicity and thereby its excretion into urine. 
The conjugation of 6-OH-melatonin to sulfate is mainly catalyzed by the enzyme 
sulfotransferase (SULT) 1A1 which shows a high affinity particularly to 6-OH-
melatonin, as compared to its parent compound melatonin (Aust et al. 2005). In 
addition, formation of 6-OH-melatonin sulfate from 6-OH-melatonin might be also 
partially catalyzed by SULT1A3, although the main role of this enzyme lies in the 
sulfate-conjugation of the monoamines dopamine and serotonin, the precursor in 
melatonin synthesis (Honma et al. 2001).  
Remarkably, the urine levels of melatonin metabolites are exactly reflective of the 
plasma melatonin levels (Schernhammer et al. 2008). Therefore, the quantification of 
urine melatonin metabolites gives detailed information about circulating melatonin 
levels.  
 
B. Metabolism of Melatonin in Breast Cells 
Many studies have assessed the expression of CYPs and SULTs in breast 
cancer cell lines and also in tissue specimens. For example, the expression of 
CYP1A1 mRNA and protein was demonstrated in tumor and adjacent histologically 
normal breast tissue by quantitative reverse transcription polymerase chain reaction 
and immunohistochemistry, respectively (Modugno et al. 2003; Haas et al. 2006). 
Also, the expression of SULT1A1- and 1A3- mRNA has been recently shown in 
breast tissue (Aust et al. 2005a).  
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However, only limited data with respect to the metabolism of melatonin in breast 
tissue exist. To date, only one study examined the role of SULT1A1 in the breast 
cancer cell lines MCF-7 (ER-α expressing) and MDA-MB231 (ER-α negative) (Aust 
et al. 2005). In this study it was shown that the mRNA levels of SULT1A1 were lower 
in the ER-α negative MDA-MB231 cells as compared to the ER-α expressing MCF-7 
cells, and that significantly more 6-OH-melatonin was sulfonated after stable 
transfection of MDA-MB231 cells with SULT1A1. This suggests an important role for 
SULT1A1 in the metabolism of melatonin in breast cancer. Another important point 
shown in this study was that sulfonation of parent melatonin was with only 1% very 
low as compared to that of its metabolite 6-OH-melatonin. Therefore, the expression 
and activity of CYP1A1 is a prerequisite for the metabolism of melatonin to 6-OH-
melatonin sulfate (Figure 17).  
 
 
 
Figure 17. Metabolism of melatonin in breast cells. The cytochrome P450 enzyme CYP1A1 
catalyzes the oxidation of melatonin (Mel) to 6-hydroxymelatonin (6-OH-Mel), which shows 
also anti-oxidant properties and which also binds to MT1, although to a lesser extent than 
melatonin. The sulfotransferases SULT1A1, and partially also SULT1A3 mediate the 
sulfonation of 6-OH-Mel to sulfate residues, which enhances its hydrophilicity. The resulting 
metabolite, 6-hydroxymelatonin sulfate (6-OH-Mel-SO42-), is then transported out of the cell. 
(Honma et al. 2001; Dubocovich et al. 2003; Tan et al. 2007). 
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4 AIMS OF THE THESIS 
 
Breast cancer is worldwide the most common cancer form among women. Although 
the mortality rates have declined in the past two decades due to earlier detection and 
better treatment options, the biomarkers currently in use have failed to predict the 
course of disease in individual cases. This suggests that there are still unknown factors 
playing a role in the development and progression of breast cancer, and their 
investigation should therefore provide additional prognostic information on the patient’s 
particular course of disease and his response to a certain therapy.  
 
It is already known that carcinogenesis and tumor growth are the result of 
uncontrolled cell division. The replication and division of a cell is coordinated by 
complexes of cyclins with cyclin-dependent kinases and their inhibitors. Failures in this 
interplay of the cell cycle regulators might lead to uncontrolled cell division and are 
associated with initiation and progression of cancer. 
It has been shown that melatonin, bound to its receptor MT1, is able to suppress 
proliferation of breast cancer cells by inhibition of cyclin D1. The efficacy of melatonin 
action is determined by its intracellular concentration and therefore by its 
biotransformation and extrusion from the cell.  
The intermediate filament protein nestin, a marker of stem/progenitor cells, is 
upregulated in highly aggressive basal-like breast cancer. In neuronal stem cells 
expressing both nestin and MT1, activation of MT1 led to enhanced cell proliferation, 
instead of inhibiting it, and to suppression of apoptosis. 
 
This thesis proposes to test a panel of molecules for their relevance and 
appropriateness as novel biomarkers for predicting relapse and/or cancer-associated 
death in breast cancer. 
 
i) It will be examined whether the expression level of any of the cell cycle regulators 
(cyclin D1, cyclin E, cyclin A, their activating phosphatase CDC25A, the cyclin-
dependent kinase inhibitors p16INK4a, p21waf1/cip1, p27kip1 and retinoblastoma protein) 
correlates with the patient’s risk of relapse or cancer-associated death. 
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ii) The expression of the melatonin receptor MT1 and of the melatonin-metabolizing 
enzymes (CYP1A1, CYP1A2, SULT1A1, SULT1A3) will be analyzed in order to 
understand the possible relevance of melatonin in the pathogenesis and/or therapy of 
breast cancer. Also, a possible correlation between MT1 and Cyclin D1 expression 
will be examined. 
 
iii) It will be investigated which breast cells express both nestin and MT1, and whether 
coexpression of MT1 with nestin is associated with tumor stage or the patient’s risk of 
relapse. 
 
 
The data obtained in this thesis will improve our molecular understanding of the 
early steps in carcinogenesis and also of tumor progression, and might give additional 
prognostic information regarding the patient’s risk of relapse and cancer-associated 
death. Moreover, the assessment of melatonin-metabolizing enzymes in breast tissue 
might be of relevance to identify patients likely to benefit from melatonin as novel 
adjuvant drug with antiproliferative and immunoenhancing properties in breast cancer 
therapy. 
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Imaging, Diagnosis, Prognosis
Cell Cycle Dysregulation Influences Survival in High
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ABSTRACT
Background: Cell cycle progression is regulated by cyclin dependent kinases (cdk) and cdk
inhibitors. Recent immunohistological studies suggested that dysregulation of cyclin A, cyclin
D, cyclin E, p16ink4, p21waf1/cip1, and p27kip1 are of prognostic value in patients with breast cancer.
Our study represents the first comprehensive immunohistochemical cell cycle marker analysis
for cdc25A, cyclin A, cyclin D, cyclin E, p16ink4, p21waf1/cip1, p27kip1, and pRb in tumor tissue and
adjacent benign breast tissue from 69 primarily untreated breast cancer patients. Methods: Im-
munhistochemistry using primary monoclonal antibodies to detect cdc 25A, cyclin A, cyclin D,
cyclin E, p16ink4, p21waf1/cip1, p27kip1, and pRb has been performed. Results: Sixty-nine patients
with untreated, invasive breast cancer (n = 69) were divided into a low/ intermediate and a high
risk group according to the St. Gallen 2005 consensus conference. High risk patients (n = 22)
had a significantly (p = 0.003) shorter mean and median survival (282.85 weeks; 383.0 weeks,
respectively) than low/intermediate risk patients (375.41 weeks; not reached yet, respectively).
A subgroup of high risk breast cancer patients characterized in addition by overexpression of
cdc25A, cyclin A, cyclin E, p16ink4a, and p27kip1 experienced a shortened mean survival of 222.03,
235.71, 257.25, 239.18, and 261.94 weeks, respectively. Regarding benign breast tissue adjacent
to breast cancer tissue, 59.4% of the patients investigated overexpressed cdc25A, 23.2% over-
expressed pRb, and 63.2% exerted dysregulation of p27kip1 while they proved to be negative for
immunohistochemical staining regarding all other markers tested. Conclusion: The immuno-
histological analyses of cdc25A, cyclin A, cyclin E, p16ink4a, and p27kip1 have the potential for
further refining the risk assessment in patients with untreated breast cancer who belong to the
high risk category defined according to the St. Gallen 2005 consensus conference. These cell
cycle markers define a subgroup of high risk patients with even higher risk of metastazation
and shortened survival. For confirmation a prospective study using standardized laboratory
procedures in a larger population is needed.
Keywords: High risk breast cancer patients, cdc25A, cyclin A, cyclin E, p16ink4a, p27kip1
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INTRODUCTION
Uncontrolled cell proliferation is a prominent feature in
tumorigenesis. Inappropriate activation of cyclin dependent ki-
nases (cdks) can result in loss of checkpoint control and thus
abnormal cellular proliferation. Cells traverse the cell cycle in
several tightly controlled phases, G1, S, G2, and M (1). Cell
cycle progression is a complex process mediated by cdks. Cdks,
a class of serine/threonine kinases, consist of catalytic subunits
that form complexes with proteins known as cyclins. Actually,
there are nine cdks, cdk1–cdk9, and 15 cyclins, cyclin A–cyclin
T known (2, 3). Cdk1 (cdc2) binds cyclin A and B to modu-
late G2–M transition, cdk2 binds cyclins A, D, and E to drive
the G1–S transition and S-phase, cdk4 and cdk6 bind cyclin D
to promote cell cycle progression through G1, and cdk7 binds
cyclin H to activate other cyclin/cdk complexes (4). The level
of activity of the holoenzymes formed by the cyclins and their
cognate cdk catalytic subunits is regulated by distinct molec-
ular mechanisms, which include phosphorylation and dephos-
phorylation of the kinase subunit (5). Cyclin expression varies
during the cell cycle. Cdk activation depends upon removal of
inhibitory Thr/Tyr phosphorylation by members of the cdc25
phosphatase family. Cdc25A expression is required for S-phase
entry and is induced in G1 by myc and E2F (6). The E2F family
of transcription factors, which control the expression of genes
needed for cell cycle progression, is controlled by Rb family
proteins, pRb and p107 (7). In addition, association with spe-
cific regulatory proteins (8) and interaction with specific cdk
inhibitors are also of importance in the regulation of cdk activ-
ity. Two different types of cdk inhibitors can be distinguished
(9, 10). First, inhibitors of cdk4 (INK4) comprise p16, p15,
p18, and p19, and inhibit specifically cyclin D-associated ki-
nases. The second type encloses the kinase inhibitor protein
family (KIP) p21, p27, and p57, that bind and inhibit the ac-
tivity of cyclin E/cdk2 and cyclin A/cdk2 complexes (3, 11,
12).
The prognostic value of individual cyclins and endoge-
nous physiologic cyclin inhibitors has yet to be validated
before entering routine clinical practice in breast cancer pa-
tients. It remains unclear whether the determination of ad-
ditional tumor biological factors, including cdc25A, cyclin
A, cyclin D, cyclin E, p16ink4, p21waf1/cip1, p27, and pRb,
provides additional information on survival and response for
the treatment of breast cancer patients with endocrine and
chemotherapy.
The aim of this investigation was to conduct a complete
cell cycle regulation analysis in a collective of untreated breast
cancer patients using the above-mentioned parameters. In ad-
dition, we wanted to determine whether cyclins/cyclin in-
hibitors may be related to risk categories for patients with
early breast cancer as defined by the St. Gallen 2005 con-
sensus panel, which classifies breast cancer patients into low-
, intermediate-, and high-risk categories (13), with regard to
the influence of these parameters on overall and disease-free
survival.
PATIENTS AND METHODS
Patients
Patients were informed of the investigational nature of this
analysis and had given written informed consent in accordance
with institutional and federal guidelines. The study protocol was
approved by the ethical committee of the institution.
Sixty-nine consecutive patients with untreated, invasive
breast cancer of whom all of the below detailed characteris-
tics were available and parameters could be determined were
included in this single hospital-based, retrospective analy-
sis. The patients were diagnosed with breast cancer at the
Kaiser Franz Josef-Spital, Vienna, Austria between 1998 and
2003. Their median follow-up was 62 months (range 25.0–92.0
months).
Patients were classified by age, tumor size, tumor grade,
number of involved lymph nodes, type of surgery, and hormone
receptor status. Lymph node dissection was performed in all
patients but one, from whom nodal status was not available.
Fifty-five patients (79.7%) had invasive ductal carcinoma, 9
(13.0%) patients had invasive lobular carcinoma, and 5 (7.3%)
patients had other histological features. Further pertinent de-
mographic features as well as their corresponding prognostic
associations with regard to survival are summarized in Table 1.
Fifteen (21.7%) patients underwent modified radical mas-
tectomy, and 54 (78.3%) underwent conservative breast surgery
followed by radiation therapy. All patients received adjuvant
chemotherapy containing anthracyclins. Estrogen receptor
positive patients were additionally treated with tamoxifen
or letrozol.
Seventeen (24.6%) of the 69 patients relapsed. Fourteen
(20.3%) patients developed distant metastases at multiple sites
involving lung (64.3%), bone (42.8%), liver (42.8%), brain
(28.6%), and skin (14.3%). These 14 patients with distant metas-
tases received polychemotherapy; among them 8 HER2/neu pos-
itive patients received in addition trastuzumab. Three (4.3%)
patients had local recurrence. They underwent modified radi-
cal mastectomy but received no further chemotherapy. Overall,
twelve (17.4%) patients died of breast cancer during follow-up.
Immunohistochemical analyses
Tumor specimens were obtained at the time of surgery be-
fore any chemo-, hormone- and radiotherapy. Formalin-fixed,
paraffin embedded blocks from the primary breast lesions were
used for all immunostaining procedures. One micrometer thick
sections were cut and mounted to coated slides. After antigen
retrieval by the microwave technique the immunostaining was
processed in an automated staining machine (Techmate 500;
DAKO, Gastrup, Denmark) following the operating manual. All
series included negative and positive controls.
Table 2 summarizes the supply of the primary monoclonal an-
tibodies to detect cdc 25A, cyclin A, cyclin D, cyclin E, p16ink4,
p21waf1/cip1, p27kip1, and pRb.
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Table 1. Patient Characteristics and the Corresponding Prognostic Association with Regard to Survival in form of Univariate Analyses According to
the St. Gallen 2005 Consensus Conference (12).
Factor Cases (n = 69) p value RR 95% CI
Age, years 0.98 1.00 0.94–1.06
< 35 2 (2.9%)
≥ 35 67 (97.1%)
Pathologic tumor size 0.66 0.90 0.56–1.43
pT1 38 (55.1%)
pT2 26 (37.7%)
pT3 4 (5.8%)
pT4 1 (1.4%)
Lymph node status < 0.001 1.24 1.19–1.38
Negative 40 (58.1%)
Positive: 1–3 lymph nodes 13 (18.8%)
Positive: 4–10 lymph nodes 11 (15.9%)
Positive: > 10 lymph nodes 5 (7.2%)
Tumor Grade 1 0.15 1.56 0.85–2.92
G1 4 (5.8%)
G2 33 (47.8%)
G3 32 (46.4%)
Hormone receptor status
Estrogen–receptor 0.21 0.48 0.16–1.51
ER-negative 25 (36.2%)
ER-positive 44 (63.8%)
Progesterone-receptor 0.22 0.45 0.12–1.65
PgR-negative 41 (59.4%)
PgR-positive 28 (40.6%)
KHER2/neu-receptor2 0.02 3.94 1.19–13.01
HER2/neu-negative2 54 (78.3%)
HER2/neu-positive 15 (21.7%)
ER = estrogen receptor; PgR = progesterone receptor.
1Grading was based on the recommendations of Elston and Ellis (15).
2HER/2neu-gene was determined as described by Isola et al. (16).
Evaluation and scoring of breast cancer
tissues in the 69 patients
The slides were independently examined by two observers
(RK and OR) who were blinded to clinical data before evalua-
tion. In case of discrepant scoring, a final consensus was reached
by using a double-headed microscope.
Cells were considered positive for cdc25A, cyclin A, cyclin
D, cyclin E, p21waf1/cip1, p27kip1, and pRb only when distinct
nuclear staining was identified. For staining of p16ink4a both
Table 2. Monoclonal Antibodies Used for Immunohistochemistry
Antibody Clone Dilution Incubation time Positive Control
cdc25A (1LabVision) DCS-120+ DCS-121 1:100 30 min Tonsil tissue
cyclinA (1LabVision) CYA06 1:20 60 min Tonsil tissue
cyclinD1 (2DAKO) DCS-6 1:80 30 min Rectum epithelium
cyclinE (1LabVision) CYE05 1:30 90 min Placenta tissue
p16ink4a (2DAKO) E6H4 1:25 30 min Tonsil tissue
p21waf1/cip1(2DAKO) SX118 1:25 30 min Gut mucosa
p27kip1 (2DAKO) SX53G8 1:250 30 min Tonsil tissue
pRb (2DAKO) Rb1 1:50 30 min Tonsil tissue
1LabVision, Westinghouse Dr. Fremont, California,, USA
2DAKO, Gostrup, Denmark
nuclear and cytoplasmatic staining were considered as positive
staining pattern.
The percentage of immunoreactive nuclei was evaluated
by scanning the whole section at medium magnification and
counting at least 500 cells using 10 high power fields (HPF; 40x
objective lens; diameter of microscopic field: 0.45 mm).
Staining intensities were classified as: no staining (0), weak
positive (1), moderate positive (2), and strong positive (3).
The immune reactive score (IRS) was evaluated by multiply-
ing the percentage of immunoreactive nuclei and the staining
736 R. Ko¨nigsberg et al.
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intensities according to the method of Remmele and Stegner
(14) considering an IRS of 3 to 12 points as positive and an IRS
below 3 points as negative.
For the p27kip1 evaluation a different scoring system was used.
In accordance to previously published data (15, 16) indicating
associations between reduced p27kip1 levels and shortened sur-
vival, p27kip1 expression was classified as low (<50% of im-
muoreactive cells) or high (≥50% of immuoreactive cells).
Evaluation and scoring of normal breast
tissues in the 69 patients
As first step, two independent observers (RK and OR) con-
firmed the benign nature of breast tissue being adjacent to the
breast cancer tissue by microscopic control of the hematoxylin
and eosin stained specimens. As next step, normal breast tissue
from 20 patients was stained with all eight antibodies as de-
scribed above (Table 2). If prominent immune reaction with a
particular antibody was observed, samples from the remaining
49 patients were stained consecutively. Evaluation and scoring
process were performed as described above.
Statistical analysis
Clinical, pathological, and molecular data were collected in a
mutually blinded fashion from 1998 to 2003. Survival rates and
follow-up data were calculated from the date of diagnosis until
the time of the last clinical appointment or the date of proved
breast cancer associated death.
The statistical evaluation of results included Fisher’s exact
test and X2 test for univariate analyses. Survival time was cal-
culated using Kaplan-Meier estimates, and differences between
survival curves were analyzed by means of the Breslow and log-
rank tests. The goal of the multivariate analyses was to evalu-
ate the associations between each immunohistochemical marker
and the new risk categories as defined by the St. Gallen con-
sensus panel 2005 (13). Multivariate analyses of the survival
time results were performed using the Cox proportional haz-
ards regression model. The endpoints used in this study were
overall survival and disease free survival. All statistical calcu-
lations were performed using the SPSS 14.0 statistical software
(Chicago, Illinois, USA).
RESULTS
Immunohistochemical results of breast cancer
tissue in the 69 breast cancer patients
Thirty-six (52%) of primary breast cancers were positive for
cdc25A immunostaining; twenty (29.0%) patients were cyclin
A positive; 40 (58%) patients were positive for cyclin D; 12
(17.4%) patients were positive for cyclin E; 25 (36.2%) patients
were positive for p21waf1/cip; 16 (23.2%) patients were posi-
tive for p16ink4a; and 30 (43.5%) patients were positive for pRb.
Regarding p27kip1 46 (66.7%) patients had low (<50%) expres-
sion, and 23 (33.3%) patients had 50% or more of immunostain
reacting cells.
Figure 1. Univariate analyses of survival in 69 breast cancer pa-
tients with and without overexpression of a) cdc25A, b) cyclin A,
c) cyclin D, d) cyclin E, e) p16ink4, f) p21waf1/cip1, g) p27 and
h) pRb.
In univariate analyses, no statistically significant association
could be observed between cdc25A, cyclin A, cyclin D, cyclin E,
p16ink4a, p21waf1/cip1, p27kip1, pRb, and overall survival (Fig. 1)
as well as disease-free survival (data not shown).
Immunohistochemical results of normal
breast tissue in the 69 breast cancer patients
In the case of cyclin A, cyclin D, cyclin E, p16ink4a, and
p21waf1/cip1, no staining at all could be observed in the first 20
patients with benign breast tissue. Thus, the benign breast tissue
of the remaining 49 patients was not stained.
Regarding cdc25A, p27kip1, and pRb, positive staining was
prominent. Fifty-two (75%) of the 69 patients’ samples were
stained with cdc25A, and 41 (59.4%) among them were im-
munohistochemically positive. Fifty-seven (82.6%) patients
were stained with p27kip1, and 36 (63.2%) among them had
less than 50% of immunostain reacting cells; in 8 patients,
no staining at all was present. Fifty-eight (84.1%) patients
were stained with pRb, among them 16 (23.2%) were im-
munohistochemically positive. In univariate analyses, no sta-
tistically significant association could be observed between
overall survival and cdc25A (p = 0.82), p27kip1 (p = 0.66),
Cell Cycle Dysregulation Influences Survival in High Risk Breast Cancer Patients 737
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pRb (p = 0.28), or disease-free survival and cdc25A (p =
0.15), p27kip1 (p = 0.80), and pRb (p = 0.15) (data not
shown).
Univariate and multivariate survival analyses
according to cdc25A, cyclin A, cyclin D, cyclin
E, p21waf1 / cip1, p16ink4a , p27kip1, pRb, and defined
risk groups
According to the St. Gallen 2005 consensus panel criteria
(13), we formed a low, an intermediate, and a high-risk group
from the 69 patients analyzed. Because the low risk group com-
prised only 3 (4.3%) patients, we pooled the patients of the
low and intermediate risk group. Thus, the low/intermediate risk
group comprised 47 (68.1%) patients, and the high risk group
22 (31.9%) patients.
Overall survival and disease-free survival of the 69 patients
were calculated in an intent-to-treat manner from the time of
diagnosis onwards (Fig. 2). The mean and the median over-
all survival of patients in the high risk group was signifi-
cantly shorter than for the better risk patients (p = 0.003).
Low/intermediate risk patients had a mean overall survival of
375.41 weeks (CI; 359.34–391.47). The median overall survival
was not reached during the entire follow-up period of median
Figure 2. Overall survival and disease-free survival in 69 patients
with primary breast cancer according to the St. Gallen 2005 Con-
sensus risk categories.
62 months yet. High risk patients had a mean overall survival
of 282.85 weeks (CI; 221.87–343.83) and a median overall sur-
vival of 383.00 weeks (CI; 37.75–728.24). Regarding disease-
free survival, low/intermediate risk patients had a mean disease-
free survival of 359.78 weeks (CI; 336.83–382.74), whereas
their median disease-free survival was not reached. High risk
patients had a mean disease-free survival of 229.63 weeks (CI;
164.19–295.07) and a median disease-free survival of 240.00
weeks (CI; 16.33–463.66) (p < 0.001). Table 3 summarizes
mean overall survival durations of the low/intermediate and
the high risk patient group separately according to the individ-
ual samples’ cell cycle marker expression analysed in univari-
ate analyses in our study. There was an obvious tendency to-
wards shortened overall survival in high risk patients expressing
cdc25A, cyclin A, cyclin E, p16ink4a, and p27kip1 with respec-
tive mean survival times of 222.03, 235.71, 257.25, 239.18, and
261.94 weeks.
However, when the traditional clinico-pathological combined
risk factors of the St. Gallen 2005 consensus panel and the
cell cycle markers investigated in this study (cdc25A, cyclin A,
cyclin D, cyclin E, p21waf1/cip1, p16ink4a, p27kip1, pRb) were all
included in a multivariate Cox regression analysis, only the es-
tablished combined risk factors positive lymphnode status and
positive HER2/neu-receptor status of the St. Gallen 2005 con-
sensus panel were found to have a significant (p < 0.005) impact
on breast cancer specific survival.
DISCUSSION
Cdk‘s and their inhibitors represent biologically important
factors which may dispose on prognostic potential for future risk
assessment in breast cancer patients. Several research groups
have investigated the link between immunohistochemically ex-
amined cell cycle regulators and prognosis, but definite molec-
ular markers describing the individual risk for patients at high
risk to relapse more accurately are still insufficient or missing
(17–19).
Table 3. Overall Survival of Low/ Intermediate Risk Versus High Risk
Patients (n = 69) Expressing cdc25A, Cyclin A, Cyclin D, Cyclin E,
p21waf1/cip1, p16ink4a ,p27kip1 and pRb Separately in Univariate
Analyses.
Survival1 (weeks) Survival1
in low/ intermidiate (weeks) in high
risk patients risk patients
cdc25A 378.58; CI2 (356.00–400.49) 222.03; CI (152.27–291.79)
cyclin A 334.60; CI (288.79–380.41) 235.71; CI (139.30–332.13)
cyclin D 380.21; CI (361.38–399.05) 305.85; CI (220.65–391.05)
cyclin E 357.13; CI (318.85–395.40) 257.25; CI (116.05–398.45)
p21waf1/cip1 334.75; CI (290.05–379.45) 318.33; CI (243.15–393.51)
p16ink4a 357.13; CI (318.85–395.40) 239.18; CI (131.22–347.13)
p27kip1 359.66; CI (339.36–379.95) 261.94; CI (172.85–351.02)
pRb 362.59; CI (333.28–391.89) 291.57; CI (205.58–377.56)
1Mean survival.
2Confidence Interval 95%.
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Our investigation represents the first comprehensive im-
munohistological assessment of relevant cell cycle markers
including cdc25A, cyclin A, cyclin D, cyclin E, p16ink4a,
p21waf1/cip1, p27kip1, and pRb expression in breast cancer tissue
and adjacent benign breast tissue of 69 breast cancer patients.
According to the St. Gallen 2005 consensus conference (13),
we grouped the patients to a low/intermediate and a high risk
cohort. High risk patients had a significantly (p = 0.003) shorter
mean and median survival periods (282.5 weeks; 383.0 weeks,
respectively) than low/intermediate risk patients (375.41 weeks;
median not reached yet, respectively) in an univariate analysis.
Including the above mentioned cell cycle markers in the St.
Gallen model of traditional prognostic factors, it was striking to
see that in particular cdc25A, cyclin A, cyclin E, p16ink4a, and
p27kip1 influenced survival. Although this influence on survival
was statistically not significant in our study, there was an obvi-
ous tendency towards a shortened overall survival (Table 3). It is
a matter of speculation whether the lack of significance is only
due to the small number of samples analyzed. However, whether
the metastatic potential in high risk breast cancer patients is de-
pendent on the dysregulation of a single cell cycle marker or of a
combined dysregulation of two or more cell cycle markers is not
known yet and represents a question to be further investigated.
Defining the individual risk of developing metastases pre-
cisely is of enormous importance for the choice of adequate
therapy during the early course of the disease because the fifteen-
year survival of patients receiving adjuvant therapy in breast
cancer has increased from 3% to 10% only (20). Recent data
support the idea of mutagenic changes early in the develop-
ment of breast cancer (21). But, the meaning of genetic changes
early in the course of breast cancer in respect to the later devel-
opment of metastatic disease and survival in low/intermediate
risk as well as in high risk patients is still an area of uncer-
tainty. Thus, we had a special interest in this study to find out
whether cdks and cdk inhibitors are overexpressed in benign
glandular epithelial cells of the breast being adjacent to the
breast cancer tissue and whether they influence metastazation
and survival. In our investigation only cdc25A, p27kip1, and
pRb were found to be positive in the immunohistochemical
stain, while all other cell cycle regulators were not. Of inter-
est, 59.4% of our patients overexpressed cdc25A, 63.2% had a
low p27kip1 expression and 23.2% overexpressed pRb in nor-
mal breast tissue adjacent to breast cancer tissue. In the case of
p27kip1 recent studies used this marker merely as positive control
for immunohistochemical staining in benign breast tissue (16,
22). Although we could not detect a significant association be-
tween cdc25A, p27kip1, and pRb expression and overall survival
or disease-free survival in low/intermediate or high risk patients,
the fact that these cell cycle regulators are expressed in normal
breast tissue adjacent to breast cancer tissue may play an impor-
tant role in the early phase of breast carcinoma tumorigenesis
and in the process of developing metastases, whereby this hy-
pothesis seems to be supported by previously published studies
(23–25).
Our results regarding the prognostic value of cdc25A, cyclin
A, cyclin E, p16ink4a, and p27kip1 are in line with others (16,
26-28), but previous studies have also yielded some contradic-
tory results regarding the prognostic value of the different cdks
and their inhibitors (15, 29, 30). Actually, it is difficult to com-
pare studies with one another because of the heterogeneity of
immunohistochemical techniques, antibodies, and scoring tech-
niques used in the different analyses as has been reviewed by
Jacobs et al. (31).
In conclusion, the data of our study demonstrate a short-
ened overall survival of high risk breast cancer patients defined
according to the St. Gallen 2005 consensus conference who ad-
ditionally overexpress cdc25A, cyclin A, cyclin E, p16ink4a, and
at a lower level p27kip1.
Considering the results presented and discussed, cell cycle
markers may have the potential of further refining the risk as-
sessment in breast cancer patients. As a consecutive step con-
firmation of our results within the scope of a prospective study
with a larger patient population and on the basis of standardized
laboratory procedures is warranted.
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Coexpression of the melatonin receptor 1 and nestin in human
breast cancer specimens
Introduction
Melatonin acts via receptor-independent antioxidative [1, 2]
and receptor-mediated mechanisms [3]. Previous studies
showed that melatonin inhibits proliferation of breast
cancer cell lines and prevents progression of malignant
breast tumors in animal models [4]. These anticancer eﬀects
of melatonin are thought to be mediated at least in part by
binding and activation of its high-aﬃnity G-protein-
coupled receptor (GPCR), the melatonin receptor (MT) 1
[5, 6]. This receptor has been detected in various human
tissues [7]. Many studies used the estrogen-sensitive breast
cancer cell line MCF-7 overexpressing MT1, and showed
that MT1 activation suppresses estrogen receptor (ER)-
induced transcription of genes important for cell prolifer-
ation and tumor progression, resulting in the inhibition of
breast cancer growth [8, 9]. Therefore, MT1 activation
induces a strong antiproliferative eﬀect in ER-expressing
breast tumors sensitive to circulating estrogens [10]. This is
important for a large number of breast cancers, which
express ER and that are responsive to anti-hormonal
therapy.
The success of this therapy, however, is often temporary
as tumors escape their estrogen responsiveness and growth
progresses [11]. With respect to this escape from estrogen
dependency, it is interesting that in an immunohistochem-
ical study in patients with breast cancer, the expression of
MT1 was found to be higher in less diﬀerentiated breast
tumors, independent of the expression of ER and also of
the progesterone receptor (PR) [12]. Therefore, MT1
expression seems to be important for additional mecha-
nisms, which could inﬂuence tumor growth independent of
Abstract: Activation of the G-protein-coupled receptor (GPCR) for
melatonin (MT1) suppresses breast cancer cell growth in experimental
models. To elucidate whether MT1 might play a role in cancer cells positive
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adjacent noncancerous (NCa) samples from 42 patients with primary breast
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estrogen signaling. For example, in breast cancer cell lines,
MT1 signaling was shown to interfere with the transcrip-
tional activity of the glucocorticoid receptor and the
retinoid receptor involving diﬀerent G-protein signaling
pathways [13]. Moreover, the inhibitory eﬀect of melatonin
on the uptake of tumor growth promoting fatty acids and
the suppression of fatty acid metabolism could be impor-
tant in these tumors [14].
In line with these ﬁndings, other studies showed that the
activation of MT1 by melatonin is indeed associated with an
induction of cell diﬀerentiation of neuronal as well as
non-neuronal cells and also of tumor cells. For example, it
induces neurite outgrowths in neuroblastoma cells and
causes neuroendocrine diﬀerentiation of prostate cancer
cells [15, 16]. In MT1-transfected Chinese hamster ovary
(CHO) cells, receptor activation by melatonin provokes
changes in cellular properties, e.g. induction of ﬁlamentous
structures, dependent on activation of theMEK1/2 ERK1/2
signaling pathway [17].
While these studies very well explain the anticancer
eﬀects of MT1 activated by melatonin, the high MT1
expression levels in cancer tissue, as found in the breast
cancer study of Dillon et al. [12] are still not easy to explain
and, therefore, another function of MT1 seems likely. Like
other GPCRs, MT1 might have the ability to become
activated independent of its ligand melatonin, thereby
changing the fate of normal and transformed cells in a still
unknown way [18, 19]. This might be of particular
signiﬁcance for tumor induction and progression and could
occur in mature cells as well as in their progenitor/stem
cells, as cells with a capacity of unlimited renewal,
diﬀerentiation and motility [20].
Similar to normal stem cells, also in cancer, a small
population of cells, termed cancer stem cells (CSC), possess
the capability for self-renewal, asymmetric cell division and
indeﬁnite proliferative capacity. These tumor-initiating
CSCs have been identiﬁed in a variety of hematological
and solid malignancies, and were also found in breast
cancer [21]. CSCs share various characteristics with normal
stem cells, but they also contain a unique and disease-
speciﬁc signature of proteins [22]. For example, nestin, an
intermediate ﬁlament protein, was originally identiﬁed as a
marker of neuroepithelial stem/progenitor cells in the brain,
but was also later found in a cell population with CSC
characteristics in many tumors, e.g. breast cancer [23–25].
It is assumed that nestin-expressing stem cells initiate a
population of dediﬀerentiated cells capable of unlimited
growth giving rise to highly undiﬀerentiated tumors. This
model for malignant transformation in the breast is
supported by the ﬁnding that high nestin levels were
associated with aggressive, poorly diﬀerentiated basal-like
breast cancer [24]. Moreover, due to their nestin expression,
endothelial cells in newly formed capillaries are thought to
have developed from nestin-positive precursor cells, and
their presence is associated with a highly aggressive
phenotype of cancer [25].
Importantly, expression of nestin together with MT1 was
found in neural stem cells [26], but a possible association of
nestin together with MT1 has not yet been evaluated in
breast cancer cells. Therefore, the present study was carried
out to elucidate whether MT1 expression in diﬀerent cells
might correspond to that of nestin. We further investigated
whether this possible coexpression might be associated with
particular features of the tumors (grading, tumor stage and
risk of relapse). Investigations were carried out in the
cancerous (Ca) and the adjacent noncancerous (NCa) parts
of breast tissue specimens from the same patient using a
novel quantitative image analysis system for the evaluation
of the immunoﬂuorescence data.
Materials and methods
Patients
Forty-two patients with primary, invasive breast carci-
noma, diagnosed and operated between 1998 and 2003 at
the Kaiser-Franz-Josef Hospital, Vienna, were enrolled in
the study. Written informed consent was obtained from all
patients, and the study was approved by the ethics
committee of the institution.
The mean age of patients at primary diagnosis was
56 ± 10 yr (range 29–76). Patients were classiﬁed as
described by Ko¨nigsberg et al. [27]. Staging was carried
out at the primary diagnosis according to the guidelines of
the International Union against Cancer (UICC). The
observation time after the date of primary diagnosis to
the date of last appointment or disease-associated death
was 67 ± 19 months, ranging from 11 to 96 months. Based
on data on patient age, tumor size, presence of tumor cells
in local lymph nodes, tumor diﬀerentiation grade, HER2
status and peritumoral vascular invasion, patients were
assigned to be at low, intermediate or high risk of local or
distant relapse [28]. From eight patients with distant
metastases, lungs were aﬀected in 87.5%, liver in 62.5%,
bone in 37.5% and brain in 25.0% of patients. Seven of 42
(16.7%) patients died from metastatic disease within the
observation time.
All tissue specimens were obtained from patients prior
to chemotherapy by surgical excision immediately after
primary diagnosis and, in our study, parts not required for
further routine diagnosis were used. All samples were
routinely subjected to pathological examination. Twenty-
nine patients had invasive ductal carcinoma, six invasive
lobular carcinoma and seven patients had tumors with
other histological features (e.g. apocrine, medullary or
mucinous carcinoma). Grading was carried out according
to Bloom and Richardson, with 4 G1, 21 G2 and 17 G3
tumors. ER (27 positive), PR (16 positive) and HER2 (19
positive) expression was routinely assessed using immuno-
histochemistry at the Institute of Bacteriology and
Pathology, Kaiser-Franz-Josef-Hospital, Vienna. The
evaluation of ER and PR status was carried out accord-
ing to the method of Remmele and Stegner [29], and
HER2 staining were regarded positive if >10% of cells
showed distinct and complete membrane staining of
HER2.
Antibodies
The rabbit polyclonal antibody against the human MT1
was purchased from Abcam, Cambridge, UK. A mouse
monoclonal antibody (mAB) against nestin (clone 10C2)
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was obtained from Millipore (Temecula, CA, USA). Both
primary antibodies were applied at a concentration of
2.5 lg/mL. The mouse mAB against CD10/CALLA (clone
56C6) and the mAB against a-SMA (clone 1A4) were both
obtained from Labvision/Neomarkers (Fremont, CA,
USA), and were applied at concentrations of 1:30 tissue
culture supernatant and 0.25 lg/mL respectively.
As secondary antibodies, we applied Alexa Fluor 488
(green) and 568 (red) labeled goat anti-rabbit (488), and
goat anti-mouse (568) antibodies at concentrations of 2 lg/
mL, which were obtained from Molecular Probes (Eugene,
OR, USA). For immunohistochemical detection of MT1, a
goat anti-rabbit/mouse antibody conjugated to horseradish
peroxidase labeled dextran (Envision) was used as a
secondary antibody and purchased from Dako Company
(Glostrup, Denmark).
For negative control, the following immunoglobulins (Ig)
were applied: rabbit anti-mouse IgG (Pierce, Rockford, IL,
USA) and mouse myeloma IgG1 (Zymed Laboratories,
South San Francisco, CA, USA).
Immunohistochemical detection of MT1
After surgical excision of the breast carcinoma and the
surrounding nonmalignant resection margin, both tissues
were routinely ﬁxed in formalin (4%), dehydrated and
embedded in paraﬃn. From tissue blocks, 1-lm sections
were prepared, mounted on adhesive slides and dried for at
least 1 hr at 65C. Thereafter, sections were deparaﬃnized
in xylene, and the endogenous enzyme activity was blocked
with 3% hydrogen peroxide in methanol for 10 min at
room temperature (RT). The sections were then processed
through a graded series of alcohols and rehydrated in
phosphate-buﬀered saline (PBS). After permeabilization in
0.1% Tween-20 in PBS for 10 min at RT, antigen retrieval
was performed using the microwave technique in 10 mm
citrate buﬀer (pH 6.0) for 10 min, followed by blocking
with 10% bovine serum albumin (BSA) in PBS for 30 min.
Thereafter, the sections were incubated with the MT1
antibody overnight at 4C in a humidiﬁed chamber. After
washing three times in PBS, the dextran polymer peroxidase
Envision System was applied for 30 min at RT. The antigen
was then visualized using the 3¢,3-diaminobenzidine chro-
mogen for 4 min. Cell nuclei were counterstained with
hematoxylin (ChemMate; Dako), rinsed with distilled
water and mounted in Mowiol (Sigma-Aldrich GmbH,
Steinheim, Germany).
Immunofluorescence staining
Antigen retrieval and blocking were performed as described
in the immunohistochemistry experiments. For MT1 stain-
ing, the sections were incubated with the MT1 antibody
overnight at 4C. This step was followed by washing three
times in PBS. Alexa Fluor 488-conjugated goat anti-
rabbit IgG was applied as secondary antibody for 1 hr at
RT.
For MT1–nestin double staining, initially, staining was
performed with an anti-nestin mAB for 1 hr (RT). This step
was followed by washing in PBS 3 · 5 min, and the staining
was completed by incubation with Alexa Fluor 568 goat
anti-mouse IgG for 1 hr at RT. Thereafter, slides were
washed in PBS and blocked again with 10% BSA in PBS
for 30 min before staining with the second primary
antibody against MT1 (overnight, 4C) was performed.
As a secondary antibody, Alexa Fluor 488-conjugated
goat anti-rabbit IgG (1 hr at RT) was used.
For CD10 single staining, heat-induced antigen retrieval
in 1 mm EDTA (pH 8.0) was performed for 10 min. No
antigen demasking was necessary for a-SMA detection.
Both antibodies were applied overnight at 4C in a
humidiﬁed chamber. After washing in PBS for 3 · 5 min,
sections were incubated with Alexa Fluor 568 goat anti-
mouse IgG for 1 hr at RT.
For negative controls, the primary antibodies were
replaced by the isotype-matched control IgG. Cell nuclei
were counterstained with 0.5 lg/mL bisbenzimide in PBS
(Hoechst 33342; Sigma, Munich, Germany). After com-
pleting the immunoﬂuorescence staining, slides were rinsed
with distilled water, dried and mounted in H-1000 Vecta-
shield medium (Vector Laboratories Inc., Burlingame, CA,
USA).
Microscopy and image collection
Sections were viewed in an Axioplan 2 microscope (Carl
Zeiss, Jena, Germany). For each tissue section, mono-
chrome images of four representative ﬁelds were recorded
from each channel with an AxioCam HRc2 Color CCD
digital camera at 10· and 40· magniﬁcation respectively.
To minimize background signals, the exposure times for the
MT1 (and other antigens) antibody staining were evaluated
for a certain magniﬁcation and kept constant between the
samples. Background subtraction was uniformly carried
out with the Axiovision 4.6 software (Carl Zeiss Vision
GmbH, Aalen, Germany).
Quantification of MT1 and nestin immunostaining
All carcinoma and corresponding noncarcinoma sections
showing distinct MT1 staining where a clear localization of
MT1 could be recognized were further analyzed for the
number of cells with MT1 and nestin immunostaining. Of
each tissue section, four representative images (40· magni-
ﬁcation) were analyzed using the Tissue-Quest 2.2 soft-
ware (TissueGnostics GmbH, Vienna, Austria). Single cells
were identiﬁed by their nuclei (blue bisbenzimide staining).
This identiﬁcation mask was then used to measure gray
values in the two corresponding channels (MT1 and nestin)
of each object in all images [30].
For the quantiﬁcation of MT1- and nestin-containing
cells, their ﬂuorescence intensity signals were plotted
against the bisbenzimide signal, as a parameter for the cell
number, in scattergrams. Each scattergram represents
average values calculated from analysis of all four images
of one entire tissue section. Based on the degree of
ﬂuorescence intensity in the negative controls (control
IgG), appropriate threshold values for positive immuno-
ﬂuorescence staining were deﬁned. Because isotype controls
were always less than 10%, the threshold for considering
the samples positive for MT1 or nestin staining was set at
10%. MT1 staining levels were considered to be diﬀerent
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between cancer and noncancer tissues, when the diﬀerence
was ‡10%.
Statistical analysis
All calculations were performed with the SPSS 14.0
statistical software package (SPSS Inc., Chicago, IL,
USA). Data are expressed as mean ± standard deviation,
and were compared with the two-sided paired or unpaired
t-test, if normally distributed. Otherwise, the two-sided
Mann–Whitney U-test was used. Diﬀerences between two
groups of categorical variables were tested with the two-
sided Fishers exact test. A value of P £ 0.05 was
considered statistically signiﬁcant.
Results
Overall, in paired samples from 37/42 patients green
staining for MT1 immunoreactivity was observed in the
Ca and adjacent NCa specimens (Fig. 1). In NCa sections,
MT1 immunoreactivity is located in myoepithelial and
luminal epithelial cells of the milk ducts. Occasionally,
green MT1-stained stromal cells are visible of normal tissue
(Fig. 1A,B). The inset in Fig. 1A further shows that MT1
immunoreactivity is mainly located in the cell membrane of
ductal epithelial cells in this specimen. This was only seen in
15/42 NCa specimens, while in 10/42 of NCa specimens, in
addition to cell membranes, cytosolic compartments were
also stained for MT1. In the remaining 15/42 MT1-positive
samples, the subcellular localization of MT1 was diﬀuse
and not clearly attributable to the membrane or the cytosol.
An analogous staining pattern for MT1 was also observed
in immunohistochemistry experiments (Fig. 1C).
In contrast to the more frequent membrane, MT1
localization in the NCa specimens, MT1 immunolocaliza-
tion in the cytosol was seen in the majority of all Ca
specimens (21/42), while preferential cell membrane stain-
ing was seen in 10/42 Ca samples. In the remaining eight
samples, the localization of MT1 was not clearly attribut-
able to either group. However, comparison of the subcel-
lular localization of MT1 in Ca and paired NCa sections
did not reveal signiﬁcant diﬀerences between the two
groups (P = 0.74). MT1 immunoﬂuorescence staining
patterns of Ca sections from a highly undiﬀerentiated
(G3) invasive ductal tumor are shown in Fig. 1D,E. Fig. 1F
represents an immunohistochemical staining for MT1 in a
better diﬀerentiated ductal carcinoma (G2). As demon-
strated in the inset of Fig. 1D, MT1 immunoreactivity is
(A) (D)
(E)(B)
(C) (F)
Fig. 1. Expression of MT1 in noncancer-
ous and cancerous breast tissue. Paraﬃn-
embedded sections from breast tissue were
stained for MT1 by immunoﬂuorescence
(A,B,D,E) and immunohistochemistry
(C,F). MT1 staining of epithelial cells in
milk ducts is seen in noncancerous tissue
(A–C). In milk ducts, outer myoepithelial
cells (M) and inner luminal cells (L) show
green MT1 ﬂuorescence (A,B) and brown
staining of MT1 with DAB (C). As shown
in the inset (arrow), MT1 staining is
mainly in the membrane. MT1 staining of
carcinoma cells (T, arrowheads in image
F) of invasive ductal tumors of G2 (F;
patient 12) and G3 (D,E; patient 17). The
area shown at higher magniﬁcation in the
inset is marked by an arrow. Green spots
in carcinoma cells suggest MT1 localiza-
tion in cytoplasmic compartments. Note
that the images (B) and (E) correspond to
(A) and (D), but are additionally count-
erstained with the DNA intercalating dye
bisbenzimide. In (C) and (F), nuclei were
counterstained with hematoxylin. Inset
bars represent 10 lm. Number of samples
correspond to that in Table 1 and Fig. 3
(panel B).
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spotted in cytoplasmic compartments in ductal epithelial
cells in this Ca specimen.
MT1 immunoreactivity in cell membranes and in cyto-
plasmic compartments, or both, was further veriﬁed by
confocal immunoﬂuorescence laser scanning microscopy
(data not shown). As nestin was previously described to be
expressed in breast tumors in myoepithelial and cancer cells
with stem cell properties [23, 24], we investigated nestin
immunolocalization with respect to that of MT1 to: (i)
conﬁrm myoepithelial localization of MT1 and (ii) identify
cancer cell subpopulations positive for nestin and MT1.
In the immunoﬂuorescence analysis, overall positive
cytoplasmic nestin staining was observed in 38/42 of
NCa, where it was located in myoepithelial cells in milk
ducts and lobules. From 31 nestin-positive Ca specimens, in
nine nestin was seen only in myoepithelial cells of
milk ducts, in another nine in myoepithelial cells and
inﬁltrating cells and in the remaining 13 in inﬁltrating
tumor cells only. In the latter, nestin was observed in tumor
cell clusters and vascular-like structures (Fig 2A and B).
Double staining for MT1 and nestin is shown in
Fig. 3A(a–c) in NCa and Ca sections from a patient with
an invasive ductal carcinoma (G2). In parts of this tumor,
intact milk ducts are still present. MT1–nestin coexpression
is found in myoepithelial cells of the milk ducts in the NCa
and Ca sections (Fig. 3Aa,b), while in image c, overlap of
MT1 and nestin staining is found in only a small fraction of
tumor cells.
(A)
(B)
(a) (b)
(c) (d)
(e) (f)
(g) (h)
Fig. 2. Immunoﬂuorescence staining of
nestin, a-SMA and CD10 in malignant
and nonmalignant breast tissue. (A): Red
nestin staining of milk ducts in malignant
(b) and nonmalignant (a) tissue. Image (b)
shows the intraductal component of an
invasive ductal carcinoma, G2, from
patient 3. (c) shows red a-SMA and (d) red
CD10 staining of milk ducts and lobules
in nonmalignant tissue. (B) These serial
sections show an apocrine tumor (G2),
obtained from patient 2. Red nestin
staining in the invasive part of the tumor,
without milk duct structures (e,f). Note,
that long stretched structures of nestin
staining (e, indicated by arrows) resemble
the pattern of a-SMA staining in picture
(g). In (f), nestin-positive cells are forming
clusters (indicated by arrowheads), which
are negative for the myoepithelial marker
CD10 (h). The arrow indicates nestin
expression in endothelial cells of a blood
vessel. (g) shows red a-SMA staining in
the invasive part of the tumor, without
milk duct structures. (h) No staining for
CD10 is observed in this tumor. Cell
nuclei were detected by staining of the
DNA with bisbenzimide (blue). Inset bars
represent 10 lm for nestin (a,b,e,f) and
CD10 (d,h), and 40 lm for a-SMA (c,g)
staining pictures.
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To estimate the percentage of cells in the Ca and NCa
samples, we applied quantitative Tissue Quest analysis. For
this analysis, paired Ca and NCa samples were chosen in
which MT1 membranous and/or cytoplasmic staining was
pronounced in a uniform pattern in the whole specimen.
This was the case for 17 patients, but for patient 17, only
(A)
(B)
(a)
(a)
(b)
(b) (c)
(d) (e) (f)
Fig. 3. MT1- (green) and nestin (red)-
co-staining in the noncancerous (a) and
cancerous parts (b,c) from breast cancer
specimens and its quantitative evaluation.
(A) (a–c) Coexpression is seen in milk
ducts in the noncancerous (a) and can-
cerous (b) parts and in cells in the invasive
component (c) from patient 3 (see B) with
a G2 invasive ductal tumor (c). In the
merged picture of green MT1 and red
nestin staining, orange to yellow staining
(arrows) indicates overlay of MT1 and
nestin ﬂuorescence. Inset bars: 10 lm.
(d–f) Quantitative evaluation of MT1-,
nestin- and MT1–nestin-coexpressing
cells. Data were obtained from Tissue-
Quest 2.2 image analysis of specimens
from patient 3 (shown above), and from
two additional patients. Noncancerous (d)
and cancerous (e) milk ducts and invasive
component (f). Note, that only patient 2
had >10% of MT1 and nestin double-
positive cells in the invasive part of the
tumor respectively. (B): Number of MT1-,
nestin- and MT1–nestin-coexpressing cells
in specimens from noncancer (a) and
invasive cancer (b) sections from breast
tumors from 17 patients. The percentage
of MT1- (black bars), nestin- (shaded
bars) and MT1–nestin (checkered bars)
coexpressing cells was calculated from
data in the scattergrams, where cells in the
upper right quadrants were considered
MT1 positive. In panel (b), the stars and
the arrows indicate patients with high
numbers of MT1- and nestin-expressing
cells, showing <10% (stars) and >10%
(arrows) of MT1–nestin-coexpressing cells
respectively. *For patient 17, NCa tissue
was not analyzable.
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the Ca tissue was available. Clinical data of these 17
patients are given in Table 1. We found that: i) 8/16 tumors
had more MT1-positive cells (>10%) in the Ca than in
adjacent NCa section; ii) in 6/16 tumors, the number of
MT1-positive cells was higher (>10%) in the NCa than in
corresponding Ca section; and that iii) the remaining two
patients showed no diﬀerence (<10%) between the NCa
and Ca sections in the amount of cells positive for MT1.
In Fig. 4A, images (a–c) and the corresponding scatter
plots (d–f) are given for the quantiﬁcation of MT1-
expressing cells in NCa and surrounding invasive Ca
specimens from a representative patient. In Fig. 4B, data
on the analysis of MT1-expressing cells from invasive Ca
and corresponding NCa sections from 16 patients (Table 1)
are depicted.
We found no signiﬁcant relationship between the amount
of MT1-expressing cells in the invasive Ca and ER, PR or
HER2 status, the menopausal status and the tumor
diﬀerentiation grade. Moreover, quantiﬁcation of cells
expressing nestin was carried out in the Ca and NCa
specimens from the 17 patients (Table 1). Nestin was found
in 13/16 NCa specimens, and in 9/17 Ca specimens.
Table 1. Characteristics of patients, whose specimens were quan-
titatively assessed for the number of MT1 and nestin-positive cells
Patient
no.
Agea
(yr) Stage Histology Grade ER PR HER-2
1 63 I Invasive ductal 1 + + )
2 47 I Apocrine 2 ) ) +
3 55 I Invasive ductal 2 ) ) +
4 68 IIA Invasive ductal 2 + ) )
5 53 IIA Invasive ductal 3 ) ) )
6 42 IIB Invasive ductal 2 ) + +
7 68 IIA Invasive ductal 2 + + )
8 75 IIA Invasive ductal 3 ) ) +
9 29 IIA Invasive ductal 3 + + +
10 71 IIIA Invasive ductal 2 + + +
11 66 IIA Invasive ductal 2 + ) )
12 49 IIA Invasive ductal 2 ) + +
13 57 IIA Medullary 3 ) ) +
14 53 IIA Invasive ductal 3 ) ) +
15 64 IIB invasive lobular 2 + + )
16 44 IIIC Invasive lobular 3 ) ) +
17 44 I Invasive ductal 3 ) ) +
Patient numbers correspond to Fig. 3B.
aAge at primary diagnosis.
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Fig. 4. Quantitative evaluation of MT1
levels in cancerous and adjacent noncan-
cerous breast specimens. (A) Immunoﬂu-
orescence staining of MT1 (green) in
nonmalignant (a) and malignant tissue (b)
from patient 15 with invasive lobular
breast carcinoma (G2). Nuclei (blue) were
counterstained with bisbenzimide and
were used for cell recognition (DNA
mean) in the image analysis. Their number
is given in the dot blots (d–f) which cor-
respond to the immunoﬂuorescence pic-
tures (a–c). Cells were analyzed for DNA
content (x) and MT1 ﬂuorescence (y). The
upper right quadrant in the dot blot shows
the number of MT1 stained cells in one
specimen. Detection thresholds are indi-
cated by black lines, which have been set
after image analysis of the negative con-
trol (noncancerous breast tissue, c,f), in
which unspeciﬁc control IgG were used
instead of the MT1 antibody. Inset bars
represent 10 lm. (B) Number of MT1-
expressing cells in specimens from non-
cancer (black bars) and invasive tumor
(gray bars) sections from breast tumors
from 17 patients. The percentage of MT1-
expressing cells was calculated from data
in the scattergrams, where cells in the
upper right quadrants were considered
MT1 positive. *For patient 17, NCa tissue
was not analyzable.
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Remarkably, these nine patients also had high MT1
staining levels (panel b in Fig. 3B). Therefore, in the next
step we investigated whether MT1 might be expressed
together with nestin in the same cell.
MT1–nestin double-positive myoepithelial cells were
found in 11/16 NCa samples (Fig. 3B image a). As shown
in Fig. 3B(b), remarkable MT1–nestin coexpression was
found in 6/17 Ca sections lacking intact milk ducts.
Representative images of MT1-, nestin- and MT1–nestin
overlay staining in invasive parts of Ca from two patients
with and without MT1–nestin coexpression are shown in
Fig. 5A and B respectively.
In Table 2 we show that MT1 and nestin co-localization
is found in six patients being in a more advanced tumor
stage (IIA–IIIC). By contrast, patients without remarkable
MT1–nestin colocalization were at a low tumor stage (2/3
in stage I). However, in this explorative study, diﬀerences in
tumor stage between the two groups did not reach
signiﬁcance (P = 0.083). In addition, interestingly, 4/6
patients with MT1–nestin coexpression had ER and PR
double-positive tumors (two with ER+/PR+/HER2+;
and two with ER+/PR+/HER2)), whereas 2/3 patients
without remarkable coexpression showed HER2-like phe-
notype (ER)/PR)/HER2+).
(A)
(b) (b)
(a) (a)
(c) (c)
(d) (d)
(B)
Fig. 5. MT1 and nestin coexpression in
invasive tumors containing >10% MT1-
and nestin-expressing, CD10-negative
cells. Immunoﬂuorescence staining for
MT1 (a), nestin (b) and the merged pic-
tures (c) are shown in specimens from a
G2 apocrine carcinoma (patient 2, A), and
from an invasive ductal G3 carcinoma
(patient 5, B). MT1 expression in nestin-
positive/CD10-negative cells is seen in
<10% in Ca sections from patient 2 (A)
and >10% in patient 5 (B). In (d), blue
stained cell nuclei in the apocrine (A) and
the invasive ductal (B) carcinoma are
shown. Inset bars: 10 lm.
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Discussion
In this study, we showed that MT1 and nestin immunore-
activity was detectable in a great majority of Ca and
adjacent NCa specimens from 42 patients with breast
cancer. MT1 staining was detected in luminal and myoepi-
thelial cells in milk ducts of NCa and also in diﬀerentiated
tumor areas, giving a considerable overlap with the nestin
staining. In invasive tumor parts, MT1 was present in single
tumor cells and cell clusters invading the stroma as well as
in perivascular cells, which were also positive for nestin.
The striking colocalization of MT1 with the intermediate
ﬁlament protein nestin raises the question about the role of
MT1 in nestin-expressing myoepithelial and also in tumor
cells in breast tissue.
Mammary gland structure constantly changes in size,
shape and function from the time of puberty to menopause,
and it is well known that myoepithelial cells play a key role
in these processes [31]. Moreover, the loss of or change in
myoepithelial cell function is a key step in the transition
from the in situ (i.e. tumor limited to the inside of the milk
duct) to invasive breast cancer, as, under normal or even
premalignant conditions, the myoepithelial cells are form-
ing a structural barrier between the luminal epithelial cells
and the surrounding stroma, thus preventing cell invasion
[31, 32]. Additionally, myoepithelial cells have been shown
to inhibit growth and invasion of breast cancer cells
through secretion of paracrine factors, like extracellular
matrix proteins and protease inhibitors [31]. These consid-
erations support our ﬁndings that MT1 is expressed in
some, but not all, nestin-positive myoepithelial cells in NCa
and Ca milk ducts. Moreover, the presence of MT1 in
luminal, nestin-negative cells, might be important, as the
majority of breast cancers are developing from these cells.
We found MT1–nestin coexpression also in carcinoma
cells in the invasive Ca parts. Both, luminal and myoepi-
thelial cells are thought to be derived from a common
precursor/stem cell, and, interestingly, in a recent experi-
ment it was shown that neural stem cells can settle in a new
microenvironment and can adopt the function of similarly
endowed mammary progenitors [33]. This could also apply
for human breast tumors. Therefore, it is interesting to
mention that the coexpression of MT and nestin had
recently been reported in a mouse neural stem cell line [26].
Cancer development and progression is characterized by
dynamic changes in the expression and function of protein
kinases which regulate mitogenesis, motility, invasion, cell
survival and angiogenesis [34]. Various alterations in the
expression or function of protein kinases or their associated
signaling pathways can lead to malignant transformation of
cells in the breast [35]. For example, overexpression of
several receptor tyrosine kinases and deregulation of the
phosphoinositide-3-kinase (PI3K) pathway were found to
contribute to the development of breast cancer [36, 37].
This consideration is important, as MT1 activation by
melatonin was found to regulate a number of diﬀerent
signaling pathways involving the second messengers cAMP,
diacylglycerol, inositol triphosphate (IP3), arachidonic acid
and intracellular Ca2+ ([Ca2+]i) [38, 39]. However, if
melatonin was used for MT1 activation in experimental
studies, rather an inhibitory eﬀect on pathways, like the
PI3K pathway, was observed, as shown by a recent study in
MCF-7 breast cancer cells, where MT1 activation by
melatonin, via coupling to G(aq), inhibited phospholipid
hydrolysis and the induction of IP3 production [6]. More-
over, an enhancement of the retinoid-induced RARa
transcriptional activity is achieved via G(aq) coupling.
Other oncostatic properties of melatonin most likely to
be conferred via binding to MT1 are related to its
interaction with estrogens and the ER [40]. For example,
via epigenetic processes, melatonin downregulates the
expression of genes responsible for the local synthesis or
activation of estrogens, e.g. aromatase. Melatonin further
inhibits telomerase activity and cyclin D1 expression
induced by estrogens, thereby modulating the cell cycle
[5]. Although these mechanisms could contribute to
potential beneﬁcial eﬀects of melatonin on tumor pro-
gression, as shown in animal models [10, 14], they are
related to the estrogen responsiveness of the cells, i.e.
requiring a functional ER. Therefore, the high levels of
MT1 found in our study also in ER-negative Ca
specimens, are diﬃcult to explain, but tumor suppressive
eﬀects of melatonin via MT1 in hormone-independent
tumors have also been described in other studies, like in
hormone refractory prostate cancer [41]. These ﬁndings
suggest additional hormone-independent functions of
MT1.
Both abundant and aberrant expressions of nestin were
previously observed under malignant transformation [42].
Table 2. Characteristics of breast cancer patients without and with
MT1 and nestin coexpressing cells in the tumor stroma
MT1–nestin coexpression
Absent
(n = 3)
Patient no.
2, 6, 17
Present
(n = 6)
Patient no. 5, 7,
9, 10, 15, 16
Tumor grade
G1 0 0
G2 2 3
G3 1 3
Stage
I 2 0
II 1 4
III 0 2
Risk of relapsea
Low 0 0
Intermediate 3 4
High 0 2
Relapse
No 1 5
Localb 2 0
Distantc 0 1
Death
Alive 3 5
Dead 0 1
Age, mean ± SD (yr) 44.6 ± 2.5 54.7 ± 15.9
aRisk categories were deﬁned as described in the Materials and
methods section.
bLocal relapse within 49 months after primary diagnosis.
cDistant metastases in the lung, brain and bone within 8 months
after primary diagnosis. This patient (16, Table 1, Fig. 3B) died
from disease 11 months after primary diagnosis.
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In a recent study, nestin upregulation in inﬁltrating
breast cancer cells with stem cell properties was found to
be associated with the highly aggressive breast cancer
subtypes [23, 24]. Moreover, in our study, high levels of
nestin were present in tumor cells invading the stroma.
Moreover, it has been shown that nestin-expressing
progenitor cells in newly tumor-initiating populations
might possess the capacity to diﬀerentiate not only into
epithelial but also into endothelial cells which would be
relevant for tumor growth and vascularization [25, 43].
Like in other tumors, a high rate of neovascularization
is considered as poor prognostic factor in breast cancer
[44].
Remarkably, higher numbers of MT1–nestin-coexpress-
ing tumor cells invading the tissue stroma were related to
a higher stage of disease, as (i) all six patients were at
stages >I and as (ii) in this subgroup of six patients both
stage III patients of the 17 quantiﬁed patients were
included. Moreover, two patients had a high risk of
relapse, if parameters like tumor size, presence of tumor
cells in local lymph nodes, tumor diﬀerentiation grade,
HER2 status and peritumoral vascular invasion (but not
hormone receptors) were taken into consideration accord-
ing to the St Gallen consensus 2005 [28]. Indeed, one
patient died from distant metastases in the lung, brain and
bone within 1 yr after primary diagnosis. By contrast,
specimens without notable MT1–nestin coexpression in
the invasive tumor derived from 3 patients being in a
lower stage (<III) tumors, where two-thirds of the patients
were still in stage I. However, these tumors were of the
ER- and PR-negative and HER2-positive phenotype,
which might explain that these patients had already an
intermediate risk of relapse despite being in a low stage of
disease. Despite these interesting ﬁndings, it should be
mentioned that the sample size in our study was relatively
low, so that further studies with a higher sample number
are necessary to conﬁrm our results.
In summary, this study revealed that MT1 is coex-
pressed with nestin in NCa and Ca in a considerable
number of cells. High levels of MT1 in the Ca when
compared with NCa specimens and the co-localization of
MT1 and nestin in breast cancer cells invading the stroma
were associated with a more advanced tumor stage and
worse prognosis in a subset of patients. This warrants
further studies on MT1-mediated signaling pathways in
nestin-expressing breast cancer cells in order to elucidate
the role and function of MT1 in the progression of breast
cancer.
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Abstract 
Background. Melatonin suppresses breast cancer cell proliferation by inhibiting the 
upregulation of estrogen-induced cyclin D1 via its G-protein coupled receptor MT1. 
Moreover, melatonin stimulates the expression of SULT1E1, an enzyme transforming 
estrogen into their inactive sulfates. However, metabolism of melatonin via 6-
hydroxylation by CYP1A1/1A2 and subsequent sulfonation by SULT1A1/1A3 decreases 
its intracellular concentration, which would have a negative impact on its oncostatic 
action in breast cancer. Patients and Methods. We performed immunohistochemical 
(IHC) analysis of MT1 and cyclin D1 in breast cancer specimens from 33 patients. Also, 
we investigated the expression of CYP1A1/1A2, SULT1A1/1A3/1E1 and cyclin D1 in 
cancer (Ca) and adjacent non-cancer (NCa) specimens from 10 breast cancer patients 
using quantitative real-time RT-PCR. Results. CYP1A1-mRNA-expression was found 
only in 3 Ca and in one NCa. CYP1A2 mRNA was below the detection limit in all 
patients. SULT1A1 was observed only in 2/10 Ca and 1/10 NCa specimens. But all 10 
Ca and NCa samples showed high SULT1A3 levels. Cyclin D1 mRNA- levels were 
found in all 10 Ca and NCa specimens. Furthermore, IHC-staining of cyclin D1 was 
observed in 27/33 Ca and correlated positively with estrogen receptor positivity 
(P=0.015). Conclusion. The low or even absent expression of CYP1A1 or CYP1A2 in 
breast cancer specimens, indicates that melatonin might be present in concentrations 
effective for cell cycle arrest, which warrants its use as a new target in breast cancer 
therapy. 
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Introduction 
Breast carcinoma is worldwide the most common cancer form among women, 
accounting for around one third of all new cancer cases each year, and its incidence is 
still increasing [1]. Estrogens have been found to play an important role in the initiation 
and progression of this disease. They stimulate cell growth and inhibit apoptosis in the 
mammary gland via their binding to their nuclear estrogen receptor alpha (ER-α). 
Therefore, drugs which interfere with estrogen signaling, represent an effective adjuvant 
treatment of ER-α-positive breast carcinomas. Melatonin, an indoleamine produced by 
the pineal gland, was found to down-regulate ER-α and to block the binding of estradiol-
ER-α-complexes to estrogen response elements (ERE) in DNA, resulting in 
suppression of estrogen-induced ER-α transcriptional activity on genes implicated in 
cell growth, division and survival [2]. One protein which is upregulated in response to 
estrogens and other mitogens and implicated in cell division is cyclin D1 [3]. Cyclin D1 
forms complexes with cyclin-dependent kinases (CDK) 4 and 6, which are key 
regulators of the progression through the G1 phase of the cell cycle. Since aberrant 
activity of cyclin D1 results in functional inactivation of the retinoblastoma proteins which 
impede E2F transcription factors important for the initiation of DNA replication, cyclin D1 
overexpression is associated with the development and progression of breast cancer, 
and occurs in up to 50 % of primary breast carcinomas [4].  
In addition to its indirect effect on cell proliferation via interaction with estrogen 
signaling, melatonin directly induces cell cycle arrest in G0/G1-phase through blockade 
of the transcription factors ATF-2 and c-jun and their interaction with the cAMP-
response element (CRE) of the cyclin D1 promoter [5]. The inhibition of cyclin D1 
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induction suggests melatonin as an effective agent also in the treatment of breast 
cancer being resistant to endocrine therapies.  
In addition to its interference with estrogen signaling which is thought to be mainly 
mediated via activation of its Gi-protein coupled receptor MT1, melatonin acts as a 
potent antioxidant and free-radical scavenger protecting against DNA damage e.g. 
caused by oxidized estrogens [6, 7]  
However, a limiting factor in the efficacy of melatonin action is its intracellular 
concentration which critically depends on inactivation by phase I cytochrome P450 
isoenzymes (CYP) and phase II conjugation enzymes. Therefore, the local expression 
and activity of metabolizing enzymes is important (Figure 1).  
As shown by studies on the hepatic metabolism of melatonin, its oxidation to 6-
hydroxymelatonin, mainly catalyzed by CYP1A2 and CYP1A1, might play a role also in 
extrahepatic tissues [8]. The metabolite 6-hydroxymelatonin exhibits also antioxidant 
effects and has been demonstrated to bind to melatonin receptors MT1 and MT2, but to 
a lesser extent than its parent compound melatonin [7, 9]. However, conjugation to 
sulfate residues reduces binding of 6-hydroxymelatonin to its targets, enhances its 
hydrophilicity and therefore its excretion into urine. For the conjugation reaction, 
sulfotransferase SULT1A1 showing a high affinity particularly to 6-hydroxymelatonin, 
was found to be important in the sulfonation of 6–hydroxymelatonin in MCF-7 breast 
cancer cells [10]. Thus, the formation of 6-hydroxymelatonin sulfate represents a major 
pathway of melatonin metabolism, which is further supported by the fact that the 
measurement of urinary levels of 6-hydroxymelatonin sulfate accurately reflects plasma 
melatonin levels [11].  
Previous studies demonstrated the expression of CYP1A1- mRNA and of CYP1A1- 
and CYP1A2- protein in tumor and adjacent histologically normal breast tissue by 
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quantitative RT-PCR and immunohistochemistry, respectively [12, 13]. Also, the 
expression of SULT1A1, SULT1A3 and SULT1E1 in malignant and surrounding non-
malignant breast tissue was demonstrated [14]. SULT1A3 has been reported to be also 
involved in the biotransformation of 6-hydroxymelatonin, although to a lesser extent 
than SULT1A1 [15]. SULT1A3 further plays a role in conjugating the monoamines 
dopamine and serotonin, the precursor of melatonin in biosynthesis, to sulfate residues 
[16]. The enzyme SULT1E1 catalyzes the conjugation of estrogens to sulfate residues, 
and protects thereby breast cancer cells from excessive estrogenic actions [2]. Since 
melatonin was shown to stimulate the expression and activity of SULT1E1, SULT1E1 
might be considered an important target in the antiproliferative action of melatonin [2]. In 
the present study, we assessed the expression of CYP1A1, CYP1A2, SULT1A1 and 
SULT1A3 considered to be relevant for the biotransformation of melatonin in breast 
tissue. In parallel, we also looked for the expression of MT1, cyclin D1 and the estrogen 
sulfotransferase SULT1E1, known targets for the oncostatic action of melatonin. For this 
purpose, we performed quantitative reverse transcription polymerase chain reaction on 
malignant and non-malignant tissue specimens obtained from 10 breast cancer 
patients. In addition, MT1 and cyclin D1 were analyzed immunohistochemically in breast 
cancer and the adjacent non-cancerous tissue specimens from 33 patients.  
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Patients and methods 
Patients and samples 
Frozen carcinomatous and adjacent histologically non-carcinomatous tissue and 
paraffin-embedded cancer tissue sections were used from 10 and 33 patients, 
respectively. All patients (mean age 59 + 11 years; range: 40 – 94) were diagnosed with 
primary, invasive breast carcinoma at the Center for Oncology and Hematology of the 
Kaiser-Franz-Josef Spital, Vienna, Austria. The study protocol was approved by the 
ethical committee of the institution and written informed consent was obtained from all 
patients. 
All samples were routinely subjected to pathological examination and only parts not 
required for further routine diagnosis were used for the study. In the routine diagnostic 
immunohistochemistry staining, 33 tumors were positive for ER-α, 16 for PR and 12 for 
HER2. 
 
RNA Isolation, quantitative (TaqMan) reverse transcription-PCR 
Frozen carcinomatous and adjacent non-malignant tissue from the same patient 
was used for the isolation of total RNA as described previously [17]. 
After reverse transcription of total RNA, real-time RT PCR was applied to evaluate 
cyclin D1, CYP1A1, CYP1A2, SULT1A1, SULT1A3 and SULT1E1 mRNA expression 
using the StepOnePlus system (Applied Biosystems) [17]. Quantitative real-time RT-
PCR was performed in an amplification mixture with a volume of 20 μl. The target gene 
amplification mixture contained 10 μl 2X TaqMan® Universal PCR Master Mix, 1 μl of 
the appropriate Gene Expression Assay, 10 ng template cDNA dissolved in 5 μl 
nuclease free water, and 4 μl nuclease free water. β-actin was used as an endogenous 
control. All amplification experiments were done in triplicate. Sequence Detection 
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Software (SDS 1.9.1, Applied Biosystems) results were imported into Microsoft Excel, 
and comparable cDNA amounts in the specimens were calculated either according to 
the 2-ΔΔCt method [18] or as described by Pfaffl [19].  
Relative gene expression values are given as the n-fold change in transcription of 
target genes normalized to β-actin as endogenous control. The sample with the highest 
detectable target gene expression was arbitrarily used as calibrator, and the obtained 
data were calculated in relation to the calibrator’s expression level. 
 
Primers and probes  
Quantitative Polymerase Chain Reaction (PCR) was performed with the following 
predesigned TaqMan® Gene Expression Assays containing intron-spanning primers 
(Applied Biosystems, Foster City, CA, USA): Cyclin D1: Hs99999004; CYP1A1: 
Hs01054797_g1; CYP1A2: Hs00167927_m1; SULT1A1: Hs00738644_m1; SULT1A3: 
Hs00413970_m1 and SULT1E1: Hs00193690_m1, β-actin: Part No 4326315E. 
 
Antibodies  
MT1: rabbit polyclonal antibody against human MT1 (Abcam, Cambridge, UK), 2.5 
µg/ml; Cyclin D1: mouse monoclonal antibody against cyclin D1 (clone DCS-6, Dako, 
Glostrup, Denmark), 1:80 of cell culture supernatant. The peroxidase-conjugated 
Envision® kit (#K4065, Dako) was applied for the secondary antibody reaction.  
Control experiments were done using rabbit anti-mouse IgG (H+L) (Pierce, 
Rockford, IL, USA) or mouse monoclonal IgG2a against Aspergillus niger glucose 
oxidase (Dako), instead of the primary antibody, respectively. 
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Immunohistochemical (IHC) detection  
IHC staining of MT1 was performed as described [20]. Staining of cyclin D1 was 
done in an analogous manner, except for antigen retrieval, which was performed by 
boiling the sections for 10 min in 1 mM EDTA buffer (pH 8.0). The anti-cyclin D1 
antibody was applied for 30 min (room temperature), whereas incubation with the anti-
MT1 antibody was done overnight (5°C).   
Light microscopy of the IHC-stained sections was performed with an Axioplan 2 
microscope (Carl Zeiss, Jena, Germany), and images were recorded with an AxioCam 
HRc2 Color CCD digital camera (Zeiss) linked to the microscope.  
Immunostaining of MT1 and cyclin D1 was assessed semi-quantitatively by two 
observers by scanning the whole section at 40x magnification to obtain 
immunoreactivity score values (IRS) between 0 (negative) and 12 (strong staining of 
>80% of cells) [21].  
 
Statistical analysis  
All statistical calculations and graphs were done with the SPSS 14.0 statistical 
software (Chicago, IL, USA). Data are expressed as mean + standard deviation, and 
normally distributed data were compared by applying the two-sided unpaired t-test. 
Possible linear relationships between MT1- and cyclin D1- scores were assessed with 
Pearson correlation. For all tests, the level of significance was set to p < 0.05. 
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Results 
Expression of CYP1A1-, CYP1A2-, SULT1A1- and SULT1A3 mRNA in malignant and 
non-malignant breast tissue 
To get insight into the metabolism of melatonin in breast tissue, we analyzed the 
expression of the cytochromes CYP1A1 and CYP1A2, and also of the sulfotransferases 
SULT1A1 and 1A3 in malignant (Ca) and adjacent non-malignant (NCa) tissue 
specimens obtained from 10 patients with quantitative real-time RT-PCR.  
CYP1A1 mRNA was found only in 3/10 patients (Figure 2b). CYP1A2 mRNA was 
below the detection limit in all 10 patients.  
Expression of SULT1A1 was observed only in two Ca and one NCa specimens 
(Figure 2c). High mRNA levels of SULT1A3 were found in the Ca and NCa specimens 
from all 10 patients (Figure 2d). In 6 patients, SULT1A3 expression was 1.4 – 8.4 -fold 
higher in NCa than in the corresponding malignant specimen. By contrast, we found up 
to 4-fold higher SULT1A3 mRNA levels in the malignant than in the adjacent non-
malignant specimens from four patients. 
 
Expression of SULT1E1- mRNA in malignant and non-malignant breast tissue 
SULT1E1, which transforms estrogens into their inactive sulfates, is an important 
target of melatonin action. We performed quantitative real-time RT-PCR analysis to 
investigate the expression of SULT1E1 in Ca and corresponding NCa specimens from 
10 breast cancer patients. We found SULT1E1 expression only in 2 Ca and 2 NCa 
specimens from three patients (data not shown). High SULT1E1 mRNA levels in both, 
Ca and NCa, were seen in one patient.  
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Expression of cyclin D1- mRNA in malignant and non-malignant breast tissue 
With respect to the role of melatonin in the inhibition of cyclin D1, we assessed the 
expression of cyclin D1 in malignant and non-malignant breast tissue.  
Quantitative real-time RT-PCR-analysis showed high mRNA levels of cyclin D1 in all 
Ca and corresponding NCa specimens from 10 patients (Figure 2a). 4 patients showed 
up to 4.8-fold higher, and 4 patients up to 3.2-fold lower cyclin D1 expression levels in 
their Ca than the adjacent NCa. No difference in cyclin D1 mRNA levels between Ca 
and NCa was found for two patients. Since cyclin D1 is a downstream target of estrogen 
signaling, we assessed a possible relationship between cyclin D1 mRNA expression 
levels and ER-α status. We found significantly higher cyclin D1 levels in the five ER-α 
positive compared to the five ER-α negative Ca specimens (n-fold change: 0.65 + 0.35 
vs. 0.16 + 0.10, P = 0.034). 
 
Immunohistochemical analysis of cyclin D1 in breast cancer tissue sections 
Due to the high expression of cyclin D1 mRNA in malignant breast tissue, we were 
also interested to take a look at the cyclin D1 protein level. As a consecutive next step, 
we conducted single IHC-staining of cyclin D1 on Ca tissue sections from 33 well-
characterized breast cancer patients, and analyzed the percentage of stained cells and 
the staining intensity, from which we calculated the immunoreactive score (IRS) ranging 
from 0 to 12. Staining of cyclin D1 in cell nuclei was observed in 27 of 33 breast cancer 
sections, with a median IRS of 3. In concordance with PCR data, the IRS of cyclin D1 
correlated positively with the ER-α-status (IRS: 4.6 + 3.4 in ERα+ vs. 0.8 + 1.6 in ERα-, 
P = 0.015) (Figure 3). 
 
 
103
  
Immunohistochemical analysis of MT1 in breast cancer tissue sections 
Since studies in breast cancer cell culture showed the involvement of MT1 in the 
antiproliferative effect of melatonin, we also investigated the expression of MT1 in 
breast cancer tissue sections obtained from 33 patients.  
We observed cytoplasmic staining of MT1 in tumor cells in 31/33 Ca tissue sections 
subjected to single IHC-staining, with a median IRS of 8. With respect to melatonin’s 
inhibitory effect in estrogen signaling, we also examined a possible relationship between 
MT1 IRS and ER-α status. However, MT1-scores were similar in ER-α-positive and –
negative specimens. As shown in Figure 3, staining of both, MT1 and cyclin D1 was 
seen in 25/33 tumor specimens, but the immunoreactive scores of MT1 were not related 
to those of cyclin D1.  
 
 
 
104
  
Discussion 
In this study we examined the expression of enzymes of biotransformation relevant 
for the metabolism of melatonin in breast cancer and its adjacent non-malignant tissue. 
We found modest CYP1A1 mRNA expression in only three out of ten patients while, as 
expected, CYP1A2 mRNA was below the detection limit in all ten cases. Therefore, in 
our patient collective, melatonin might not be oxidized to 6-hydroxymelatonin, which is a 
prerequisite for conjugation to sulfate residues by SULT1A1 and 1A3. Moreover, 
SULT1A1 mRNA was expressed in three of ten patients being different to those with 
CYP1A1 expression. Since SULT1A1 is regarded the main responsible enzyme for the 
formation of 6-hydroxymelatonin sulfate, these data indicate that in our patient collective 
melatonin might be present in concentrations effective for its oncostatic action.  
 
Recent studies showed two main pathways of melatonin metabolism in humans. In 
one case, melatonin’s interaction with reactive oxygen species results in formation of 
N1-acetyl-N2-formyl-5-methoxykynuramine, while in the other case melatonin is oxidized 
to 6-hydroxymelatonin. The first pathway is found predominately in brain, while the 
second is important for circulating melatonin [7]. The latter reaction is mainly catalyzed 
by the phase-I-enzymes CYP1A1 and hepatic 1A2, as shown by Ma et al [8]. We found 
CYP1A1 mRNA only in three out of ten patients, were it was expressed in the Ca 
specimens and in one case additionally in the surrounding NCa tissue. Moreover, none 
of the 10 patients showed expression of CYP1A2 in their Ca or NCa specimens. This 
finding is in accordance with a previous study on human breast tissue showing no 
CYP1A2 expression as assessed by quantitative RT-PCR [12]. However, contrary to 
our results, Modugno et al found high levels of CYP1A1 mRNA in more than 90% of 
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both, Ca and adjacent NCa specimens, and an immunohistochemical study showed 
faint cytoplasmic staining of CYP1A2 in breast tumors [12, 13].  
Due to our findings of modest CYP1A1 mRNA expression in only three and the 
lacking CYP1A2 expression in all examined patients, we hypothesize that melatonin 
might not be metabolized to 6-hydroxymelatonin in at least seven patients. A recent 
study from our lab clearly showed that formation of 6-hydroxymelatonin is a prerequisite 
for sulfonation by SULT1A1, since application of melatonin to SULT1A1-transfected 
MCF-7- and MDA-MB 231 cells resulted in only 1% of the amount of 6-
hydroxymelatoninsulfate formed after incubation with 6-hydroxymelatonin [10]. Since 
the patients with SULT1A1 expression were not identical to those with CYP1A1 
expression, melatonin might not be metabolized to 6-hydroxymelatoninsulfate in our 
examined patient collective. However, sulfonation of 6-hydroxymelatonin might be also 
partially catalyzed by SULT1A3, as shown by Honma et al [15]. Analysis of SULT1A3 
expression in our patient collective showed considerable mRNA levels in Ca and NCa 
specimens from all ten patients. This implicates that a partial biotransformation of 
melatonin to 6-hydroxmelatonin sulfate might be possible in the three patients with 
CYP1A1 expression.  
On the other hand we should also consider that polymorphisms in the genes 
encoding CYP1A1, CYP1A2 and SULT1A1 have been described in breast cancer, 
which might apply also for our patient collective [22]. Since the primers applied in our 
experiment specifically bind to one variant of the respective enzyme-encoding gene, a 
possible genetic polymorphism might be the reason for the low expression levels of 
CYP1A1, CYP1A2 and SULT1A1 in our patient collective. Remarkably, the different 
genotypes might show an altered enzymatic activity, resulting in either decreased 
inactivation or enhanced metabolic activation of drugs and mutagens. Besides possible 
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single nucleotide polymorphisms, hypermethylation in the SULT1A1 gene promoter has 
been described to occur in around 60% of breast cancer specimens, leading to 
transcriptional silencing of the SULT1A1 gene [23]. This finding might have also an 
impact on the sulfonation and hence deactivation of estrogens, because SULT1A1 was 
shown to be involved in the sulfonation of DNA-damaging catecholestrogens, but also of 
estradiol in high (micromolar) concentrations [15, 24].  
 
Sulfonation of estrogens is an important mechanism for the regulation of estrogen 
activity, as estrogen sulfates do not bind to the estrogen receptor [24]. SULT1E1 shows 
a high affinity for estrogens at nanomolar concentrations and is therefore regarded the 
main estrogen metabolizing enzyme, thereby affecting the availability of the hormone in 
breast cells and consequently cell proliferation [24]. With respect to the role of SULT1E1 
in controlling estrogen activity in breast tissue and due to the property of melatonin of 
stimulating the expression and activity of SULT1E1, we assessed mRNA levels of 
SULT1E1 in our patient collective [2]. However, SULT1E1 was below the detection limit 
in seven of ten patients, and high SULT1E1 mRNA levels in both, Ca and adjacent NCa 
tissue were observed only in one patient. Since our investigation showed only minute 
amounts of both, SULT1E1 and SULT1A1 mRNA levels in our patient collective, 
estrogens might not be sulfated and might therefore bind to their estrogen receptor, 
starting with the transcription of genes required for cell division, like cyclin D1.  
 
Cyclin D1 was recently reported to be a target in the antiproliferative action of 
melatonin [5]. In MCF-7 cells, physiologic (nanomolar) concentrations of melatonin were 
shown to prevent the induction of cyclin D1 transcription via interaction with the cAMP 
response element binding site in the cyclin D1 promoter [5]. Because many 
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antiproliferative effects of melatonin at nanomolar concentrations are mediated via its Gi 
-protein coupled receptor MT1, we investigated whether the expression of cyclin D1 
would correspond to that of MT1 [6]. Our PCR results show high cyclin D1 mRNA levels 
in Ca and NCa specimens from all patients. Four of ten patients had even three-fold 
higher cyclin D1 levels in their NCa as compared to their adjacent Ca. This finding 
seems at first glance contradictory, since cyclin D1 expression is associated with cell 
proliferation. However, we should consider that NCa parts were derived from breast 
cancer specimens, and although apparently healthy looking, changes in the expression 
pattern could already precede signs of macroscopic malignant transformation. In 
agreement with our PCR data, we found cyclin D1 immunostaining in 27 of 33 Ca 
specimens. As expected from the induction of cyclin D1 transcription by estrogen 
signaling, in both experiments, significantly higher cyclin D1 levels were found in ER-α 
positive than in ER-α negative tumors. Similar findings of cyclin D1-overexpression 
preferentially in tissues of ER-α-positive breast cancers, have been previously reported 
by using quantitative real-time PCR and immunohistochemistry, [4, 25].  
 
In this study, 31 of 33 breast Ca specimens showed intense immunostaining of MT1 
in cancer cells. Accordingly, previous immunohistochemical and immunofluorescence 
studies, including our own, reported high MT1 protein levels in breast cancer tissue 
specimens [26] [20]. In agreement with these studies, in our present investigation, we 
did not find any relationship between MT1 levels and ER-status.  
 
In conclusion, the low or even absent expression of melatonin-metabolizing enzymes in 
breast cancer specimens, suggests that melatonin might be present in concentrations 
effective for its antiproliferative effect. This might be of relevance for the application of 
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melatonin as adjuvant drug with antioxidant, immunoenhancing and sleep-regulating 
properties in the management of breast cancer patients.  
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 Figure legends 
Figure 1. Biotranformation limits the antiproliferative effect of melatonin. Melatonin (Mel) induces cell 
cycle arrest of breast cancer cells through multiple mechanisms, resulting in downregulation of cyclin D1, 
which is responsible for G1-S-transition. These mechanisms include i) binding to the Gi-protein coupled 
melatonin receptor MT1, resulting in decreased levels of cyclic adenosine monophosphate (cAMP) 
required for interaction with the cyclin D1 promoter, ii) direct blockade of the transcription factor c-jun by 
melatonin, and iii) direct inhibition of binding of the estradiol (E2)-estrogen receptor-alpha (ER-α)-complex 
to estrogen-response elements in the cyclin D1 promoter. These effects depend on the intracellular 
concentration of melatonin. Therefore, enhanced biotransformation of melatonin due to expression of 
CYP1A1/1A2 and SULT1A1/1A3 in breast cancer cells decreases the intracellular melatonin levels due to 
formation of 6-hydroxymelatonin and its subsequent sulfonation and excretion.  
 
Figure 2. Expression of (a) cyclin D1, (b) CYP1A1, (c) SULT1A1 and (D) SULT1A3 mRNA in cancer (grey 
bars) and adjacent non-cancer (shaded bars) tissue from 10 patients. Relative mRNA expression levels 
were determined by quantitative TaqMan RT-PCR, and the values were normalized to β-actin as 
endogenous control. mRNA values represent the average + standard deviation of  triplicates, and are 
given as the n-fold change to the sample with the highest detectable target gene expression (calibrator).  
 
Figure 3. Immunohistochemical analysis of MT1- and cyclin D1- expression in tumor cells of invasive 
breast cancer sections obtained from 33 patients. The immunoreactivity score (IRS) of cyclin D1 (shaded 
bars) and MT1 (black bars) is depicted for each patient. Also, the estrogen receptor (ER)- α status is 
given for each patient. The IRS was calculated by multiplicating the percentage of stained tumor cells with 
the staining intensity, as described in the methods part. IRS=0, no staining; IRS=12, intense staining of > 
80% of tumor cells. 
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Certificate for the TissueFaxs Cell Analysis Software, Tissue Gnostics GmbH, 
1020 Vienna  
Communication Skills Training at the Institute of Pathophysiology, Medical 
University of Vienna 
Presentation Technique Course at Wirtschaftsförderungsinstitut (WIFI), Währinger 
Gürtel 97, 1180 Vienna 
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? Original Manuscripts 
Königsberg R, Rögelsperger O, Jäger W, Thalhammer T, Klimpfinger M, 
DeSantis M, Hudec M and Dittrich C. Cell Cycle Dysregulation influences Survival 
in High Risk Breast Cancer Patients. Cancer Invest. 2008 Aug; 26(7): 734-40. 
 
Rögelsperger O, Ekmekcioglu C, Jäger W, Klimpfinger M, Königsberg R, Krenbek 
D, Sellner F and Thalhammer T. Co-Expression of the Melatonin Receptor MT1 
and Nestin in Human Breast Cancer Specimens. J Pineal Res. 2009 May; 46: 422-
32. 
 
Rögelsperger O, Wlcek K, Ekmekcioglu C, Svoboda M, Königsberg R, 
Klimpfinger M, Jäger W and Thalhammer T. Expression of Melatonin-Metabolizing 
Enzymes and Cyclin D1 in Human Breast Cancer. Submitted for publication to 
Acta Oncol. 
 
 
? Poster-Presentations 
Svoboda M, Rögelsperger O, Wlcek K, Liedauer R, Jäger W and Thalhammer T. 
Organic Anion Transporters (SLCO/OATP) in paclitaxel sensitive and resistant 
ovarian cancer cell line A2780 and A2780-ADR, 3rd PhD Symposium, Medical 
University of Vienna, June 2007. 
 
Svoboda M, Rögelsperger O, Wlcek K, Liedauer R, Jäger W and Thalhammer T. 
Paclitaxel resistance in the adriamycin-resistant ovarian cancer cell line A2780: 
Role of SLCO uptake transporters, 5th International Symposium on Targeted 
Anticancer Therapies, Amsterdam, March 2007. 
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Svoboda M, Liedauer R, Rögelsperger O, Wlcek K, Jäger W and Thalhammer T. 
Multidrug Resistance Transporters in Ovarian Cancer Cells, 6th International 
Symposium on Minimal Residual Cancer, University of Hamburg, September 
2007. 
 
Rögelsperger O, Svoboda M, Huber S, Krenbek D, Königsberg R, Klimpfinger M, 
Jäger W and Thalhammer T. Characterization of Melatonin Receptor (MT1) 
Expression in Human Primary Breast Cancer Specimens, Joint Meeting of the 
Slovak Physiological Society and the Physiological Society and the Federation of 
European Physiological Societies, Bratislava, September 2007. 
 
Rögelsperger O, Ekmekcioglu C, Svoboda M, Königsberg R, Klimpfinger M, 
Jäger W and Thalhammer T. The Impact of the Melatonin Receptor (MT) 1 on 
Breast Cancer Progression, The Gordon Research Conference on Pineal Gland 
Biology, Barga (Lucca), April 2008. 
 
Rögelsperger O, Ekmekcioglu C, Svoboda M, Königsberg R, Klimpfinger M, Jäger 
W and Thalhammer T. Melatonin Receptor (MT)1 and Nestin Coexpression: an 
Indicator of More Advanced Breast Cancer?, EACR20 – 20th Meeting of the 
European Association for Cancer Research, Lyon, July 2008, and Symposium of 
the Center for Physiology, Pathophysiology and Immunology of the Medical 
University of Vienna, September 2008. 
 
Krenbek D, Rögelsperger O, Ellinger I and Thalhammer T. Expression of the 
Melatonin Receptors MT1 and MT2 in Human Hepatocellular Carcinoma Cells, 
Symposium of the Center for Physiology, Pathophysiology and Immunology of the 
Medical University of Vienna, September 2008. 
 
? Oral Presentation 
The Melatonin Receptor MT1 and the Intermediate Filament Protein Nestin are 
Co-Expressed in a Subgroup of Human Primary Breast Cancer, 4th PhD 
Symposium, Medical University of Vienna, 28. – 29. May 2008. 
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